KR20170116500A - Organic light-emitting compound and organic electroluminescent device using the same - Google Patents

Organic light-emitting compound and organic electroluminescent device using the same Download PDF

Info

Publication number
KR20170116500A
KR20170116500A KR1020160044337A KR20160044337A KR20170116500A KR 20170116500 A KR20170116500 A KR 20170116500A KR 1020160044337 A KR1020160044337 A KR 1020160044337A KR 20160044337 A KR20160044337 A KR 20160044337A KR 20170116500 A KR20170116500 A KR 20170116500A
Authority
KR
South Korea
Prior art keywords
group
synthesis
aryl
hrms
mat
Prior art date
Application number
KR1020160044337A
Other languages
Korean (ko)
Inventor
김충한
손호준
Original Assignee
주식회사 두산
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 두산 filed Critical 주식회사 두산
Priority to KR1020160044337A priority Critical patent/KR20170116500A/en
Priority to PCT/KR2017/001668 priority patent/WO2017179809A1/en
Publication of KR20170116500A publication Critical patent/KR20170116500A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/80[b, c]- or [b, d]-condensed
    • C07D209/82Carbazoles; Hydrogenated carbazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D251/00Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/24Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to three ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91Dibenzofurans; Hydrogenated dibenzofurans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00Luminescent, e.g. electroluminescent, chemiluminescent materials
    • C09K11/06Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
    • H01L51/0067
    • H01L51/5056
    • H01L51/5072
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K50/00Organic light-emitting devices
    • H10K50/10OLEDs or polymer light-emitting diodes [PLED]
    • H10K50/14Carrier transporting layers
    • H10K50/15Hole transporting layers
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K50/00Organic light-emitting devices
    • H10K50/10OLEDs or polymer light-emitting diodes [PLED]
    • H10K50/14Carrier transporting layers
    • H10K50/16Electron transporting layers
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K85/00Organic materials used in the body or electrodes of devices covered by this subclass
    • H10K85/60Organic compounds having low molecular weight
    • H10K85/649Aromatic compounds comprising a hetero atom
    • H10K85/654Aromatic compounds comprising a hetero atom comprising only nitrogen as heteroatom

Abstract

본 발명은 발광능이 우수한 신규의 화합물 및 이를 하나 이상의 유기물층에 포함함으로써 발광효율, 구동 전압, 수명 등의 특성이 향상된 유기 전계 발광 소자에 관한 것이다.The present invention relates to an organic electroluminescent device having improved luminous efficiency, driving voltage, lifetime, and the like by incorporating a novel compound having excellent luminous efficiency into one or more organic layers.

Description

유기 발광 화합물 및 이를 이용한 유기 전계 발광 소자 {ORGANIC LIGHT-EMITTING COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME} TECHNICAL FIELD [0001] The present invention relates to an organic electroluminescent compound, and an organic electroluminescent device using the same. BACKGROUND ART [0002]

본 발명은 신규한 유기 발광 화합물 및 이를 이용한 유기 전계 발광 소자에 관한 것으로, 보다 상세하게는 전자 주입 및 수송능 등이 우수한 신규한 피리미딘 유도체 화합물 및 이를 하나 이상의 유기물층에 포함함으로써 발광효율, 구동 전압, 수명 등의 특성이 향상된 유기 전계 발광 소자에 관한 것이다.The present invention relates to a novel organic luminescent compound and an organic electroluminescent device using the same. More particularly, the present invention relates to a novel pyrimidine derivative compound having excellent electron injection and transport ability, And lifetime of the organic electroluminescent device.

1950년대 Bernanose의 유기 박막 발광 관측을 시점으로 1965년 안트라센 단결정을 이용한 청색 전기발광으로 이어진 유기 전계 발광 (electroluminescent, EL) 소자(이하, 간단히 '유기 EL 소자'로 칭함)에 대한 연구는 1987년 탕(Tang)에 의하여 정공층과 발광층의 기능층으로 나눈 적층구조의 유기 EL 소자가 제시되었다. 이후 고효율, 고수명의 유기 EL 소자를 만들기 위하여, 소자 내 각각의 특징적인 유기물 층을 도입하는 형태로 발전하여 왔으며, 이에 사용되는 특화된 물질의 개발로 이어졌다. A study on organic electroluminescent (EL) devices (hereinafter simply referred to as "organic EL devices") led to blue electroluminescence using anthracene single crystals in 1965 based on observation of organic thin film luminosity of Bernanose in the 1950s, (Tang) and a functional layer of a light emitting layer. In order to produce high efficiency and high number of organic EL devices, the organic EL device has been developed to introduce each characteristic organic material layer in the device, leading to the development of specialized materials used therefor.

유기 전계 발광 소자는 두 전극 사이에 전압을 걸어 주면 양극에서는 정공이 주입되고, 음극에서는 전자가 유기물층으로 주입된다. 주입된 정공과 전자가 만났을 때 엑시톤(exciton)이 형성되며, 이 엑시톤이 바닥상태로 떨어질 때 빛이 나게 된다. 이때 유기물층으로 사용되는 물질은 그 기능에 따라, 발광 물질, 정공 주입 물질, 정공 수송 물질, 전자 수송 물질, 전자 주입 물질 등으로 분류될 수 있다. In the organic electroluminescent device, when a voltage is applied between two electrodes, holes are injected into the anode, and electrons are injected into the organic layer from the cathode. When the injected holes and electrons meet, an exciton is formed. When the exciton falls to the ground state, light is emitted. The material used as the organic material layer may be classified into a light emitting material, a hole injecting material, a hole transporting material, an electron transporting material, and an electron injecting material depending on its function.

유기 EL 소자의 발광층 형성재료는 발광색에 따라 청색, 녹색, 적색 발광 재료로 구분될 수 있다. 그밖에, 보다 나은 천연색을 구현하기 위한 발광재료로 노란색 및 주황색 발광재료도 사용된다. 또한, 색순도의 증가와 에너지 전이를 통한 발광 효율을 증가시키기 위하여, 발광 재료로서 호스트/도펀트 계를 사용할 수 있다. 도판트 물질은 유기 물질을 사용하는 형광 도판트와 Ir, Pt 등의 중원자(heavy atoms)가 포함된 금속 착체 화합물을 사용하는 인광 도판트로 나눌 수 있다. 이러한 인광 재료의 개발은 이론적으로 형광에 비해 4배까지의 발광 효율을 향상시킬 수 있어 인광 도판트 뿐만 아니라 인광 호스트 재료들에 대해 관심이 집중되고 있다. The light emitting layer forming material of the organic EL device can be classified into blue, green and red light emitting materials depending on the luminescent color. In addition, yellow and orange light emitting materials are also used as light emitting materials for realizing better color. Further, in order to increase the color purity and increase the luminous efficiency through energy transfer, a host / dopant system can be used as a light emitting material. The dopant material can be divided into a fluorescent dopant using an organic material and a phosphorescent dopant using a metal complex compound containing heavy atoms such as Ir and Pt. The development of such a phosphorescent material can theoretically improve the luminous efficiency up to 4 times as compared with that of fluorescence, and attention is focused on phosphorescent host materials as well as phosphorescent dopants.

현재까지 정공 주입층, 정공 수송층. 정공 차단층, 전자 수송층으로는, 하기 화학식으로 표현된 NPB, BCP, Alq3 등이 널리 알려져 고, 발광 재료는 안트라센 유도체들이 형광 도판트/호스트 재료로서 보고되고 있다. 특히 발광재료 중 효율 향상 측면에서 큰 장점을 가지고 있는 인광 재료로서는 Firpic, Ir(ppy)3, (acac)Ir(btp)2 등과 같은 Ir을 포함하는 금속 착체 화합물이 청색, 녹색, 적색 도판트 재료로 사용되고 있다. 현재까지는 CBP가 인광 호스트 재료로 우수한 특성을 나타내고 있다. Up to now, hole injecting layer, hole transporting layer. As the hole blocking layer and the electron transporting layer, NPB, BCP, Alq 3 and the like represented by the following formulas are widely known, and an anthracene derivative as a light emitting material has been reported as a fluorescent dopant / host material. In particular Firpic, Ir as a phosphorescent material that has a great advantage in improving the efficiency aspects of the light-emitting material (ppy) 3, (acac) Ir (btp) 2 Ir metal complex compound is a blue, green and red host material that includes such as . So far, CBP has shown excellent properties as a phosphorescent host material.

Figure pat00001
Figure pat00001

Figure pat00002
Figure pat00002

그러나 기존의 재료들은 발광 특성 측면에서는 유리한 면이 있으나, 유리전이온도가 낮고 열적 안정성이 매우 좋지 않아 유기 EL 소자에서의 수명 측면에서 만족할만한 수준이 되지 못하고 있다. However, existing materials have advantages in terms of light emitting properties, but their glass transition temperature is low and their thermal stability is not very good, which is not satisfactory in terms of lifetime in organic EL devices.

본 발명은 유기 전계 발광 소자에 적용할 수 있으며, 전자 주입 및 수송능 등이 모두 우수한 신규 유기 화합물을 제공하는 것을 목적으로 한다. It is an object of the present invention to provide a novel organic compound which can be applied to an organic electroluminescent device and has excellent electron injection and transporting ability.

또한, 본 발명은 상기 신규 유기 화합물을 포함하여 낮은 구동전압과 높은 발광효율을 나타내며 수명이 향상되는 유기 전계 발광 소자를 제공하는 것을 또 다른 목적으로 한다.It is another object of the present invention to provide an organic electroluminescent device including the novel organic compound and exhibiting a low driving voltage and a high luminous efficiency and having an improved lifetime.

상기 목적을 달성하기 위하여 본 발명은 하기 화학식 1로 표시되는 화합물을 제공한다.In order to achieve the above object, the present invention provides a compound represented by the following general formula (1).

[화학식 1][Chemical Formula 1]

Figure pat00003
Figure pat00003

여기서,here,

L1 및 L2는 서로 동일하거나 상이하며, 단일결합, C6~C18의 아릴렌기 또는 핵원자수 5 내지 18의 헤테로아릴렌기이며,L 1 and L 2 are the same or different and each is a single bond, a C 6 to C 18 arylene group or a heteroarylene group having 5 to 18 nuclear atoms,

R1 및 R2는 서로 동일하거나 상이하며, 각각 독립적으로 C6~C60의 아릴기 또는 핵원자수 5 내지 60의 헤테로아릴기이며;R 1 and R 2 are the same or different and are each independently a C 6 to C 60 aryl group or a heteroaryl group having 5 to 60 nuclear atoms;

Ar1 및 Ar2는 서로 상이하며, 각각 독립적으로 C6~C60의 아릴기 또는 핵원자수 5 내지 60의 헤테로아릴기이며, Ar 1 and Ar 2 are different from each other and are each independently a C 6 to C 60 aryl group or a heteroaryl group having 5 to 60 nuclear atoms,

X1, X2 및 X3는 서로 동일하거나 상이하며, 각각 독립적으로 N 또는 C(R3)이며, 적어도 2개 이상은 N이며;X 1 , X 2 and X 3 are the same or different and are each independently N or C (R 3 ), and at least two are N;

R3는 서로 동일하거나 상이하며, 각각 독립적으로 수소, 중수소, 할로겐, 시아노기, 니트로기, C1~C40의 알킬기, C2~C40의 알케닐기, C2~C40의 알키닐기, C3~C40의 시클로알킬기, 핵원자수 3 내지 40의 헤테로시클로알킬기, C6~C60의 아릴기, 핵원자수 5 내지 60의 헤테로아릴기, C1~C40의 알킬옥시기, C6~C60의 아릴옥시기, C3~C40의 알킬실릴기, C6~C60의 아릴실릴기, C1~C40의 알킬보론기, C6~C60의 아릴보론기, C6~C60의 아릴포스핀기, C6~C60의 아릴포스핀옥사이드기 및 C6~C60의 아릴아민기로 이루어진 군으로부터 선택되고, R 3 are the same or different and are each independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, nitro, C 1 to C 40 alkyl, C 2 to C 40 alkenyl, C 2 to C 40 alkynyl, A C 3 to C 40 cycloalkyl group, a heterocycloalkyl group having 3 to 40 nuclear atoms, a C 6 to C 60 aryl group, a heteroaryl group having 5 to 60 nuclear atoms, a C 1 to C 40 alkyloxy group, A C 6 to C 60 aryloxy group, a C 3 to C 40 alkylsilyl group, a C 6 to C 60 arylsilyl group, a C 1 to C 40 alkylboron group, a C 6 to C 60 arylboron group, C 6 ~ C 60 aryl phosphine group, C 6 ~ C 60 aryl phosphine oxide group, and a C 6 ~ C 60 aryl group of an amine of is selected from the group consisting of,

L1, L2의 아릴렌기 및 헤테로아릴렌기와 R1 내지 R3 및 Ar1 내지 Ar2의 아릴기 및 헤테로아릴기는 각각 독립적으로, 중주소, 시아노기, 할로겐, C1~C40의 알킬기, C2~C40의 알케닐기, C2~C40의 알키닐기, C3~C40의 시클로알킬기, 핵원자수 3 내지 40의 헤테로시클로알킬기, C6~C60의 아릴기, 핵원자수 5 내지 60의 헤테로아릴기, C1~C40의 알킬옥시기, C6~C60의 아릴옥시기,C3~C40의 알킬실릴기, C6~C60의 아릴실릴기, C1~C40의 알킬보론기, C6~C60의 아릴보론기, C6~C60의 아릴포스핀기, C6~C60의 아릴포스핀옥사이드기 및 C6~C60의 아릴아민기로 이루어진 군에서 선택된 1종 이상으로 치환될 수 있으며, 복수개의 치환기로 치환될 경우 이들은 서로 동일하거나 상이할 수 있다.Aryl group and a heteroaryl group of L 1, L 2 alkylene group and R 1 to R 3 and Ar 1 to the aryl group Ar 2, and heteroaryl groups, each independently, a quartet cow, a cyano group, a halogen, C alkyl group of 1 ~ C 40 , A C 2 to C 40 alkenyl group, a C 2 to C 40 alkynyl group, a C 3 to C 40 cycloalkyl group, a heterocycloalkyl group having 3 to 40 nuclear atoms, a C 6 to C 60 aryl group, the number of 5 to 60 heteroaryl group, C 1 ~ C 40 alkyloxy group of, C 6 ~ C 60 aryloxy group, C 3 ~ alkylsilyl group of C 40, C 6 ~ C 60 aryl silyl group, C of 1 ~ C 40 group of an alkyl boron, C 6 ~ C group 60 arylboronic of, C 6 ~ C 60 aryl phosphine group, C 6 ~ C 60 aryl phosphine oxide group, and a C 6 ~ arylamine group of C 60 of And when they are substituted with a plurality of substituents, they may be the same or different from each other.

또한, 본 발명은 (i) 양극, (ii) 음극, 및 (iii) 상기 양극과 음극 사이에 개재(介在)된 1층 이상의 유기물층을 포함하는 유기 전계 발광 소자로서, 상기 1층 이상의 유기물층 중 적어도 하나는 상기 화학식 1로 표시되는 화합물을 포함하는 것을 특징으로 하는 유기 전계 발광 소자를 제공한다. The present invention also provides an organic electroluminescent device comprising (i) a positive electrode, (ii) a negative electrode, and (iii) at least one organic material layer interposed between the positive electrode and the negative electrode, One is an organic electroluminescent device comprising a compound represented by the general formula (1).

본 발명에서 "알킬"은 탄소수 1 내지 40의 직쇄 또는 측쇄의 포화 탄화수소에서 유래되는 1가의 치환기를 의미한다. 이의 예로는 메틸, 에틸, 프로필, 이소부틸, sec-부틸, 펜틸, iso-아밀, 헥실 등을 들 수 있으나, 이에 한정되지는 않는다.In the present invention, "alkyl" means a monovalent substituent derived from a linear or branched saturated hydrocarbon having 1 to 40 carbon atoms. Examples thereof include, but are not limited to, methyl, ethyl, propyl, isobutyl, sec-butyl, pentyl, iso-amyl and hexyl.

본 발명에서 "알케닐(alken일)"은 탄소-탄소 이중 결합을 1개 이상 가진탄소수 2 내지 40의 직쇄 또는 측쇄의 불포화 탄화수소에서 유래되는 1가의 치환기를 의미한다. 이의 예로는 비닐(vin일), 알릴(all일), 이소프로펜일(isopropen일), 2-부텐일(2-buten일) 등을 들 수 있으나, 이에 한정되지는 않는다.In the present invention, "alkenyl" means a monovalent substituent derived from a linear or branched unsaturated hydrocarbon having 2 to 40 carbon atoms and having at least one carbon-carbon double bond. Examples thereof include, but are not limited to, vinyl (vinyl), allyl (all), isopropenyl (isopropenyl), and 2-butenyl (2-butenyl).

본 발명에서"알키닐(alkyn일)"은 탄소-탄소 삼중 결합을 1개 이상 가진탄소수 2 내지 40의 직쇄 또는 측쇄의 불포화 탄화수소에서 유래되는 1가의 치환기를 의미한다. 이의 예로는 에티닐(ethyn일), 2-프로파닐(2-propyn일) 등을 들 수 있으나, 이에 한정되지는 않는다.In the present invention, "alkynyl" means a monovalent substituent derived from a straight-chain or branched-chain unsaturated hydrocarbon having 2 to 40 carbon atoms and having at least one carbon-carbon triple bond. Examples thereof include, but are not limited to, ethynyl (ethyn yl), 2-propanyl (2-propynyl), and the like.

본 발명에서 "아릴"은 단독 고리 또는 2이상의 고리가 조합된탄소수 6 내지 40의 방향족 탄화수소로부터 유래된 1가의 치환기를 의미한다. 또한, 2 이상의 고리가 서로 단순 부착(pendant)되거나 축합된 형태도 포함될 수 있다. 이러한 아릴의 예로는 페닐, 나프틸, 페난트릴, 안트릴 등을 들 수 있으나, 이에 한정되지는 않는다."Aryl" in the present invention means a monovalent substituent derived from an aromatic hydrocarbon having 6 to 40 carbon atoms in which a single ring or two or more rings are combined. Also, a form in which two or more rings are pendant or condensed with each other may be included. Examples of such aryl include, but are not limited to, phenyl, naphthyl, phenanthryl, anthryl, and the like.

본 발명에서 "헤테로아릴"은 핵원자수 5 내지 40의 모노헤테로사이클릭 또는 폴리헤테로사이클릭 방향족 탄화수소로부터 유래된 1가의 치환기를 의미한다. 이때, 고리 중 하나 이상의 탄소, 바람직하게는 1 내지 3개의 탄소가 N, O, S 또는 Se와 같은 헤테로원자로 치환된다. 또한, 2 이상의 고리가 서로 단순 부착(pendant)되거나 축합된 형태도 포함될 수 있고, 나아가 아릴기와의 축합된 형태도 포함될 수 있다. 이러한 헤테로아릴의 예로는 피리딜, 피라지닐, 피리미디닐, 피리다지닐, 트리아지닐과 같은 6-원 모노사이클릭 고리, 페녹사티에닐(phenoxathien일), 인돌리지닐(indolizin일), 인돌릴(indol일), 퓨리닐(purin일), 퀴놀릴(quinol일), 벤조티아졸(benzothiazole), 카바졸릴(carbazol일)과 같은 폴리사이클릭 고리 및 2-퓨라닐, N-이미다졸릴, 2-이속사졸릴, 2-피리디닐, 2-피리미디닐 등을 들 수 있으나, 이에 한정되지는 않는다."Heteroaryl" in the present invention means a monovalent substituent derived from a monoheterocyclic or polyheterocyclic aromatic hydrocarbon having 5 to 40 nuclear atoms. Wherein at least one of the carbons, preferably one to three carbons, is replaced by a heteroatom such as N, O, S or Se. In addition, a form in which two or more rings are pendant or condensed with each other may be included, and further, a condensed form with an aryl group may be included. Examples of such heteroaryls include 6-membered monocyclic rings such as pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl and triazinyl, phenoxathienyl, indolizinyl, indole, A polycyclic ring such as a carbamoyl group, a carbamoyl group, a carbamoyl group, a carbamoyl group, a carbamoyl group, a carbamoyl group, a carbamoyl group, a carbamoyl group, , 2-isoxazolyl, 2-pyridinyl, 2-pyrimidinyl, and the like, but are not limited thereto.

본 발명에서 "아릴옥시"는 RO-로 표시되는 1가의 치환기로, 상기 R은 탄소수 5 내지 40의 아릴을 의미한다. 이러한 아릴옥시의 예로는 페닐옥시, 나프틸옥시, 디페닐옥시 등을 들 수 있으나, 이에 한정되지는 않는다.In the present invention, "aryloxy" means a monovalent substituent represented by RO-, and R represents aryl having 5 to 40 carbon atoms. Examples of such aryloxy include, but are not limited to, phenyloxy, naphthyloxy, diphenyloxy, and the like.

본 발명에서 "알킬옥시"는 R'O-로 표시되는 1가의 치환기로, 상기 R'는 탄소수 1 내지 40의 알킬을 의미하며, 직쇄(linear), 측쇄(branched) 또는 사이클릭(cyclic) 구조를 포함할 수 있다. 알킬옥시의 예로는 메톡시, 에톡시, n-프로폭시, 1-프로폭시, t-부톡시, n-부톡시, 펜톡시 등을 들 수 있으나, 이에 한정되지는 않는다.In the present invention, "alkyloxy" means a monovalent substituent group represented by R'O-, wherein R 'represents alkyl having 1 to 40 carbon atoms, and may be a linear, branched or cyclic structure . ≪ / RTI > Examples of alkyloxy include, but are not limited to, methoxy, ethoxy, n-propoxy, 1-propoxy, t-butoxy, n-butoxy and pentoxy.

본 발명에서 "아릴아민"은 탄소수 6 내지 40의 아릴로 치환된 아민을 의미한다."Arylamine" in the present invention means an amine substituted with aryl having 6 to 40 carbon atoms.

본 발명에서 "시클로알킬"은 탄소수 3 내지 40의 모노사이클릭 또는 폴리사이클릭 비-방향족 탄화수소로부터 유래된 1가의 치환기를 의미한다. 이러한 사이클로알킬의 예로는 사이클로프로필, 사이클로펜틸, 사이클로헥실, 노르보닐(norborn일), 아다만틴(adamantine) 등을 들 수 있으나, 이에 한정되지는 않는다."Cycloalkyl" in the present invention means a monovalent substituent derived from a monocyclic or polycyclic non-aromatic hydrocarbon having 3 to 40 carbon atoms. Examples of such cycloalkyl include, but are not limited to, cyclopropyl, cyclopentyl, cyclohexyl, norbornyl, adamantine, and the like.

본 발명에서 "헤테로시클로알킬"은 핵원자수 3 내지 40의 비-방향족 탄화수소로부터 유래된 1가의 치환기를 의미하며, 고리 중 하나 이상의 탄소, 바람직하게는 1 내지 3개의 탄소가 N, O, S 또는 Se와 같은 헤테로 원자로 치환된다. 이러한 헤테로시클로알킬의 예로는 모르폴린, 피페라진 등을 들 수 있으나, 이에 한정되지는 않는다."Heterocycloalkyl" in the present invention means a monovalent substituent derived from a non-aromatic hydrocarbon having 3 to 40 nuclear atoms, wherein at least one of the carbons, preferably one to three carbons, Or < RTI ID = 0.0 > Se. ≪ / RTI > Examples of such heterocycloalkyl include, but are not limited to, morpholine, piperazine, and the like.

본 발명에서 "알킬실릴"은 탄소수 1 내지 40의 알킬로 치환된 실릴이고, "아릴실릴"은 탄소수 5 내지 40의 아릴로 치환된 실릴을 의미한다.In the present invention, "alkylsilyl" means silyl substituted with alkyl having 1 to 40 carbon atoms, and "arylsilyl" means silyl substituted with aryl having 5 to 40 carbon atoms.

본 발명에서 "축합고리"는 축합 지방족 고리, 축합 방향족 고리, 축합 헤테로지방족 고리, 축합 헤테로방향족 고리 또는 이들의 조합된 형태를 의미한다.In the present invention, the term "condensed rings" means condensed aliphatic rings, condensed aromatic rings, condensed heteroaliphatic rings, condensed heteroaromatic rings, or a combination thereof.

본 발명의 화합물은 열적 안정성 및 발광 특성이 우수하기 때문에 유기 전계 발광 소자의 유기물층의 재료로 사용될 수 있다. Since the compound of the present invention is excellent in thermal stability and luminescence properties, it can be used as a material of an organic material layer of an organic electroluminescent device.

특히, 본 발명의 화합물을 전자 수송 재료로 사용할 경우, 종래의 호스트 재료에 비해 우수한 발광 성능, 낮은 구동전압, 높은 효율 및 장수명을 갖는 유기 전계 발광 소자를 제조할 수 있고, 나아가 성능 및 수명이 향상된 풀 칼라 디스플레이 패널도 제조할 수 있다.In particular, when the compound of the present invention is used as an electron transporting material, it is possible to manufacture an organic electroluminescent device having superior light emitting performance, lower driving voltage, higher efficiency and longer life time than conventional host materials, A full color display panel can also be manufactured.

이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.

1. 신규 유기 화합물1. New organic compounds

본 발명의 화합물 피리미딘계의 유기발광 화합물은 기존 전자 주입 및 수송 재료에 비해 발광 효율이 좋고 재료의 수명특성이 뛰어나 소자의 구동 수명이 매우 우수할 뿐만 아니라 전력 효율의 상승을 유도하여 소비전력이 개선된 OLED소자를 제조할 수 있는 장점이 있다.The compound pyrimidine-based organic light-emitting compound of the present invention is superior in luminous efficiency and lifetime characteristics of a material compared with the conventional electron injection and transporting material, so that the device has an excellent driving life and induces an increase in power efficiency, There is an advantage that an improved OLED device can be manufactured.

구체적으로, 본 발명에서 제공하는 신규 유기 화합물은 하기 화학식 1로 표시되는 것을 특징으로 한다:Specifically, the novel organic compounds provided by the present invention are characterized by being represented by the following formula (1)

[화학식 1][Chemical Formula 1]

Figure pat00004
Figure pat00004

여기서,here,

L1 및 L2는 서로 동일하거나 상이하며, 단일결합, C6~C18의 아릴렌기 또는 핵원자수 5 내지 18의 헤테로아릴렌기이며,L 1 and L 2 are the same or different and each is a single bond, a C 6 to C 18 arylene group or a heteroarylene group having 5 to 18 nuclear atoms,

R1 및 R2는 서로 동일하거나 상이하며, 각각 독립적으로 C6~C60의 아릴기 또는 핵원자수 5 내지 60의 헤테로아릴기이며;R 1 and R 2 are the same or different and are each independently a C 6 to C 60 aryl group or a heteroaryl group having 5 to 60 nuclear atoms;

Ar1 및 Ar2는 서로 상이하며, 각각 독립적으로 C6~C60의 아릴기 또는 핵원자수 5 내지 60의 헤테로아릴기이며, Ar 1 and Ar 2 are different from each other and are each independently a C 6 to C 60 aryl group or a heteroaryl group having 5 to 60 nuclear atoms,

X1, X2 및 X3는 서로 동일하거나 상이하며, 각각 독립적으로 N 또는 C(R3)이며, 적어도 2개 이상은 N이며;X 1 , X 2 and X 3 are the same or different and are each independently N or C (R 3 ), and at least two are N;

R3는 서로 동일하거나 상이하며, 각각 독립적으로 수소, 중수소, 할로겐, 시아노기, 니트로기, C1~C40의 알킬기, C2~C40의 알케닐기, C2~C40의 알키닐기, C3~C40의 시클로알킬기, 핵원자수 3 내지 40의 헤테로시클로알킬기, C6~C60의 아릴기, 핵원자수 5 내지 60의 헤테로아릴기, C1~C40의 알킬옥시기, C6~C60의 아릴옥시기, C3~C40의 알킬실릴기, C6~C60의 아릴실릴기, C1~C40의 알킬보론기, C6~C60의 아릴보론기, C6~C60의 아릴포스핀기, C6~C60의 아릴포스핀옥사이드기 및 C6~C60의 아릴아민기로 이루어진 군으로부터 선택되고, R 3 are the same or different and are each independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, nitro, C 1 to C 40 alkyl, C 2 to C 40 alkenyl, C 2 to C 40 alkynyl, A C 3 to C 40 cycloalkyl group, a heterocycloalkyl group having 3 to 40 nuclear atoms, a C 6 to C 60 aryl group, a heteroaryl group having 5 to 60 nuclear atoms, a C 1 to C 40 alkyloxy group, A C 6 to C 60 aryloxy group, a C 3 to C 40 alkylsilyl group, a C 6 to C 60 arylsilyl group, a C 1 to C 40 alkylboron group, a C 6 to C 60 arylboron group, C 6 ~ C 60 aryl phosphine group, C 6 ~ C 60 aryl phosphine oxide group, and a C 6 ~ C 60 aryl group of an amine of is selected from the group consisting of,

L1, L2의 아릴렌기 및 헤테로아릴렌기와 R1 내지 R3 및 Ar1 내지 Ar2의 아릴기 및 헤테로아릴기는 각각 독립적으로, 중주소, 시아노기, 할로겐, C1~C40의 알킬기, C2~C40의 알케닐기, C2~C40의 알키닐기, C3~C40의 시클로알킬기, 핵원자수 3 내지 40의 헤테로시클로알킬기, C6~C60의 아릴기, 핵원자수 5 내지 60의 헤테로아릴기, C1~C40의 알킬옥시기, C6~C60의 아릴옥시기,C3~C40의 알킬실릴기, C6~C60의 아릴실릴기, C1~C40의 알킬보론기, C6~C60의 아릴보론기, C6~C60의 아릴포스핀기, C6~C60의 아릴포스핀옥사이드기 및 C6~C60의 아릴아민기로 이루어진 군에서 선택된 1종 이상으로 치환될 수 있으며, 복수개의 치환기로 치환될 경우 이들은 서로 동일하거나 상이할 수 있다.Aryl group and a heteroaryl group of L 1, L 2 alkylene group and R 1 to R 3 and Ar 1 to the aryl group Ar 2, and heteroaryl groups, each independently, a quartet cow, a cyano group, a halogen, C alkyl group of 1 ~ C 40 , A C 2 to C 40 alkenyl group, a C 2 to C 40 alkynyl group, a C 3 to C 40 cycloalkyl group, a heterocycloalkyl group having 3 to 40 nuclear atoms, a C 6 to C 60 aryl group, the number of 5 to 60 heteroaryl group, C 1 ~ C 40 alkyloxy group of, C 6 ~ C 60 aryloxy group, C 3 ~ alkylsilyl group of C 40, C 6 ~ C 60 aryl silyl group, C of 1 ~ C 40 group of an alkyl boron, C 6 ~ C group 60 arylboronic of, C 6 ~ C 60 aryl phosphine group, C 6 ~ C 60 aryl phosphine oxide group, and a C 6 ~ arylamine group of C 60 of And when they are substituted with a plurality of substituents, they may be the same or different from each other.

피리미딘계 화합물에 페난트렌이나 카바졸이 도입된 유도체는 삼중항 에너지가 높고 안정한 구조를 기본으로 하는 코어(Core)로써 특히 페난트렌 또는 카바졸의 작용기를 치환하였을 전자 수송 능력이 향상되어 전력 효율의 상승을 유도하는 구조로 효율 특성을 극대화 할 수 있는 전자 주입 및 수송 재료로써의 장점이 있다. 특히 R1, R2, Ar1 및 Ar2위치에 방향족 고리 및 헤테로 방향족 고리가 각각 독립적으로 치환되었을 때 평면구조를 개선하여 열적 안정도를 높일 뿐만 아니라 전자 이동을 좋게 하여 전자 수송층 재료로 적합하다.Phenanthrene or carbazole-derived derivatives in the pyrimidine-based compounds are cores based on a structure having a high triplet energy and a stable structure. Especially, when the functional groups of phenanthrene or carbazole are substituted, electron transport ability is improved, So that it is advantageous as an electron injecting and transporting material capable of maximizing efficiency characteristics. In particular, when the aromatic ring and the heteroaromatic ring are independently substituted at the R 1 , R 2 , Ar 1 and Ar 2 positions, the planar structure is improved to improve the thermal stability as well as to improve the electron mobility, and thus it is suitable as an electron transport layer material.

본 발명의 바람직한 한 구현 예에 따르면, 상기 Ar1 및 Ar2는 서로 상이하며, 각각 독립적으로 C6~C60의 아릴기인 것을 특징으로 할 수 있다.According to a preferred embodiment of the present invention, Ar 1 and Ar 2 are different from each other, and each independently is a C 6 to C 60 aryl group.

본 발명의 바람직한 한 구현 예에 따르면, 상기 X1 및 X2는 각각 독립적으로 N이고, X3는 N 또는 C(R3)에서 선택되고, 상기 Ar1 및 Ar2는 서로 상이하며, 각각 독립적으로 페닐 또는 바이페닐에서 선택될 수 있다.According to a preferred embodiment of the present invention, X 1 and X 2 are each independently N, X 3 is selected from N or C (R 3 ), Ar 1 and Ar 2 are different from each other, May be selected from phenyl or biphenyl.

본 발명의 바람직한 한 구현 예에 따르면, 상기 R1 및 R2는 서로 동일하거나 상이하며, 각각 독립적으로 C6~C60의 아릴기 또는 핵원자수 5 내지 60의 헤테로아릴기에서 선택될 수 있으며, 바람직하게는 R1 또는 R2 중 적어도 하나는 하기 화학식 2 내지 5의 치환기로 이루어진 군으로부터 선택되는 것일 수 있다:According to a preferred embodiment of the present invention, R 1 and R 2 may be the same or different and each independently selected from a C 6 to C 60 aryl group or a heteroaryl group having 5 to 60 nuclear atoms , preferably at least one of R 1 or R 2 may be one selected from the group consisting of substituents of formulas 2 to 5:

[화학식 2](2)

Figure pat00005
Figure pat00005

[화학식 3](3)

Figure pat00006
Figure pat00006

[화학식 4][Chemical Formula 4]

Figure pat00007
Figure pat00007

[화학식 5][Chemical Formula 5]

Figure pat00008
Figure pat00008

여기서,here,

*는 상기 화학식 1에 결합되는 부분을 의미하고;* Represents a moiety bonded to Formula 1;

X4 내지 X26은 서로 동일하고 상이하며, 각각 독립적으로 N 또는 C(R5)이며,X 4 to X 26 are the same or different and are each independently N or C (R 5 )

R5는 서로 동일하거나 상이하며, 각각 독립적으로 수소, 중수소, 할로겐, 시아노기, 니트로기, C1~C40의 알킬기, C2~C40의 알케닐기, C2~C40의 알키닐기, C3~C40의 시클로알킬기, 핵원자수 3 내지 40의 헤테로시클로알킬기, C6~C60의 아릴기, 핵원자수 5 내지 60의 헤테로아릴기, C1~C40의 알킬옥시기, C6~C60의 아릴옥시기, C3~C40의 알킬실릴기, C6~C60의 아릴실릴기, C1~C40의 알킬보론기, C6~C60의 아릴보론기, C6~C60의 아릴포스핀기, C6~C60의 아릴포스핀옥사이드기 및 C6~C60의 아릴아민기로 이루어진 군으로부터 선택되고, R 5 are the same or different and are each independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, nitro, C 1 to C 40 alkyl, C 2 to C 40 alkenyl, C 2 to C 40 alkynyl, A C 3 to C 40 cycloalkyl group, a heterocycloalkyl group having 3 to 40 nuclear atoms, a C 6 to C 60 aryl group, a heteroaryl group having 5 to 60 nuclear atoms, a C 1 to C 40 alkyloxy group, A C 6 to C 60 aryloxy group, a C 3 to C 40 alkylsilyl group, a C 6 to C 60 arylsilyl group, a C 1 to C 40 alkylboron group, a C 6 to C 60 arylboron group, C 6 ~ C 60 aryl phosphine group, C 6 ~ C 60 aryl phosphine oxide group, and a C 6 ~ C 60 aryl group of an amine of is selected from the group consisting of,

R5의 알킬기, 시클로알킬기, 헤테로시클로알킬기, 아릴기, 헤테로아릴기, 알킬옥시기, 아릴옥시기, 알킬실릴기, 아릴실릴기, 알킬보론기, 아릴보론기, 아릴포스핀기, 아릴포스핀옥사이드기 및 아릴아민기는 각각 독립적으로, C1~C40의 알킬기, C2~C40의 알케닐기, C2~C40의 알키닐기, C3~C40의 시클로알킬기, 핵원자수 3 내지 40의 헤테로시클로알킬기, C6~C60의 아릴기, 핵원자수 5 내지 60의 헤테로아릴기, C1~C40의 알킬옥시기, C6~C60의 아릴옥시기,C3~C40의 알킬실릴기, C6~C60의 아릴실릴기, C1~C40의 알킬보론기, C6~C60의 아릴보론기, C6~C60의 아릴포스핀기, C6~C60의 아릴포스핀옥사이드기 및 C6~C60의 아릴아민기로 이루어진 군으로부터 선택된 1종 이상으로 치환될 수 있으며, 복수개의 치환기로 치환될 경우 이들은 서로 동일하거나 상이할 수 있다.R 5 is an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, an alkyloxy group, an aryloxy group, an alkylsilyl group, an arylsilyl group, an alkylboron group, an arylboron group, an arylphosphine group, The oxides and arylamine groups are each independently selected from the group consisting of a C 1 to C 40 alkyl group, a C 2 to C 40 alkenyl group, a C 2 to C 40 alkynyl group, a C 3 to C 40 cycloalkyl group, A C 6 to C 60 aryl group, a heteroaryl group having 5 to 60 nuclear atoms, a C 1 to C 40 alkyloxy group, a C 6 to C 60 aryloxy group, a C 3 to C 6 heteroaryl group, 40 alkylsilyl group, C 6 ~ C 60 aryl silyl group, C 1 ~ C 40 group of an alkyl boron, C 6 ~ C group 60 arylboronic of, C 6 ~ aryl phosphine of C 60 pingi, C 6 ~ C aryl phosphine oxide group and a C 6 ~ 60 may be substituted with at least one member selected from the group consisting of an aryl amine of the C 60, the case be substituted with a plurality of substituents, they same or another It may be different.

본 발명의 바람직한 한 구현 예에 따르면, 본 발명의 화학식1로 표시되는 화합물은 보다 구체적으로 아래의 화합물로 이루어진 군에서 선택될 수 있으나, 이에 한정되는 것은 아니다.According to one preferred embodiment of the present invention, the compound represented by formula (1) of the present invention may be selected from the group consisting of the following compounds, but is not limited thereto.

Figure pat00009
Figure pat00009

Figure pat00010
Figure pat00010

Figure pat00011
Figure pat00011

Figure pat00012
Figure pat00012

2. 유기 전계 발광 소자2. Organic electroluminescent device

한편, 본 발명의 다른 측면은 상기한 본 발명에 따른 화학식 1로 표시되는 화합물을 포함하는 유기 전계 발광 소자(유기 EL 소자)에 관한 것이다.Another aspect of the present invention relates to an organic electroluminescent device (organic EL device) comprising the compound represented by the general formula (1) according to the present invention described above.

보다 구체적으로, 본 발명에 따른 유기 전계 발광 소자는 양극(anode), 음극(cathode) 및 상기 양극과 음극 사이에 개재(介在)된 1층 이상의 유기물층을 포함하며, 상기 1층 이상의 유기물층 중 적어도 하나는 상기 화학식 1로 표시되는 화합물을 포함한다. 이때, 상기 화합물은 단독으로 사용되거나, 또는 2 이상이 혼합되어 사용될 수 있다.More specifically, the organic electroluminescent device according to the present invention includes at least one anode, an anode, and at least one organic layer sandwiched between the anode and the cathode, and at least one of the one or more organic layers Include the compounds represented by the above formula (1). At this time, the compounds may be used alone or in combination of two or more.

상기 1층 이상의 유기물층은 정공주입층, 정공수송층, 발광보조층, 발광층, 전자수송층 및 전자주입층 중 어느 하나 이상일 수 있고, 이 중에서 적어도 하나의 유기물층은 상기 화학식 1로 표시되는 화합물을 포함할 수 있다. 바람직하게는 상기 화학식 1의 화합물을 포함하는 유기물층은 전자수송층일 수 있다.The at least one organic material layer may include at least one of a hole injecting layer, a hole transporting layer, a light emitting auxiliary layer, a light emitting layer, an electron transporting layer, and an electron injecting layer. have. Preferably, the organic material layer containing the compound of Formula 1 may be an electron transporting layer.

이러한 본 발명의 유기 전계 발광 소자의 구조는 특별히 한정되지 않으나, 기판, 양극, 정공주입층, 정공수송층, 발광보조층, 발광층, 전자수송층 및 음극이 순차적으로 적층된 구조일 수 있다. 이때, 상기 정공주입층, 정공수송층, 발광보조층, 발광층, 전자수송층 및 전자주입층 중 하나 이상은 상기 화학식 1로 표시되는 화합물을 포함할 수 있고, 바람직하게는 정공수송층, 전자저지층, 발광보조층이 상기 화학식 1로 표시되는 화합물을 포함할 수 있다. 한편 상기 전자수송층 위에는 전자주입층이 추가로 적층될 수 있다.The structure of the organic electroluminescent device of the present invention is not particularly limited, but may be a structure in which a substrate, an anode, a hole injecting layer, a hole transporting layer, a light emitting auxiliary layer, a light emitting layer, an electron transporting layer and a cathode are sequentially laminated. At least one of the hole injecting layer, the hole transporting layer, the light emitting auxiliary layer, the light emitting layer, the electron transporting layer, and the electron injecting layer may include the compound represented by Formula 1, and preferably includes a hole transporting layer, The auxiliary layer may include a compound represented by the above formula (1). On the other hand, an electron injection layer may be further stacked on the electron transport layer.

본 발명의 유기 전계 발광 소자의 구조는 전극과 유기물층 계면에 절연층 또는 접착층이 삽입된 구조일 수 있다.The structure of the organic electroluminescent device of the present invention may be a structure in which an insulating layer or an adhesive layer is inserted into the interface between the electrode and the organic layer.

본 발명의 유기 전계 발광 소자는 상기 유기물층 중 1층 이상이 상기 화학식 1로 표시되는 화합물을 포함하는 것을 제외하고는, 당업계에 공지된 재료 및 방법으로 유기물층 및 전극을 형성하여 제조할 수 있다.The organic electroluminescent device of the present invention can be produced by forming an organic material layer and an electrode by materials and methods known in the art, except that at least one of the organic material layers includes the compound represented by the above formula (1).

상기 유기물층은 진공 증착법이나 용액 도포법에 의하여 형성될 수 있다. 상기 용액 도포법의 예로는 스핀 코팅, 딥코팅, 닥터 블레이딩, 잉크젯 프린팅 또는 열 전사법 등이 있으나, 이에 한정되지는 않는다.The organic material layer may be formed by a vacuum deposition method or a solution coating method. Examples of the solution coating method include, but are not limited to, spin coating, dip coating, doctor blading, inkjet printing, or thermal transfer.

본 발명의 유기 전계 발광 소자 제조 시 사용되는 기판은 특별히 한정되지 않으나, 실리콘 웨이퍼, 석영, 유리판, 금속판, 플라스틱 필름 및 시트 등을 사용할 수 있다.The substrate used in the fabrication of the organic electroluminescent device of the present invention is not particularly limited, but silicon wafer, quartz, glass plate, metal plate, plastic film and sheet can be used.

또, 양극 물질로는 바나듐, 크롬, 구리, 아연, 금과 같은 금속 또는 이들의 합금; 아연산화물, 인듐산화물, 인듐 주석 산화물(ITO), 인듐 아연 산화물(IZO)과 같은 금속 산화물; ZnO:Al 또는 SnO2:Sb와 같은 금속과 산화물의 조합; 폴리티오펜, 폴리(3-메틸티오펜), 폴리[3,4-(에틸렌-1,2-디옥시)티오펜](PEDT), 폴리피롤 또는 폴리아닐린과 같은 전도성 고분자; 및 카본블랙 등을 들 수 있으나, 이에 한정되지는 않는다.Examples of the positive electrode material include metals such as vanadium, chromium, copper, zinc, and gold, or alloys thereof; Metal oxides such as zinc oxide, indium oxide, indium tin oxide (ITO), and indium zinc oxide (IZO); ZnO: Al or SnO 2: a combination of a metal and an oxide such as Sb; Conductive polymers such as polythiophene, poly (3-methylthiophene), poly [3,4- (ethylene-1,2-dioxy) thiophene] (PEDT), polypyrrole or polyaniline; And carbon black, but are not limited thereto.

또, 음극 물질로는 마그네슘, 칼슘, 나트륨, 칼륨, 타이타늄, 인듐, 이트륨, 리튬, 가돌리늄, 알루미늄, 은, 주석, 또는 납과 같은 금속 또는 이들의 합금; 및 LiF/Al 또는 LiO2/Al과 같은 다층 구조 물질 등을 들 수 있으나, 이에 한정되지는 않는다.The negative electrode material may be a metal such as magnesium, calcium, sodium, potassium, titanium, indium, yttrium, lithium, gadolinium, aluminum, silver, tin or lead or an alloy thereof; And multi-layer structure materials such as LiF / Al or LiO 2 / Al, but are not limited thereto.

또한, 정공 주입층, 정공 수송층, 전자 주입층 및 전자 수송층은 특별히 한정되는 것은 아니며, 당 업계에 알려진 통상의 물질을 사용할 수 있다.The hole injecting layer, the hole transporting layer, the electron injecting layer and the electron transporting layer are not particularly limited, and ordinary materials known in the art can be used.

이하 본 발명을 실시예를 통하여 상세히 설명하면 다음과 같다. 단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명이 하기 실시예에 의해 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail with reference to examples. However, the following examples are illustrative of the present invention, and the present invention is not limited by the following examples.

[[ 준비예Preparation Example 1] One]

4-([1,1'-4 - ([1,1'- 바이페닐Biphenyl ]-4-일)-6-(3-] -4-yl) -6- (3- 브로모Bromo -5-(피리딘-3-일)페닐)-2--5- (pyridin-3-yl) phenyl) -2- 페닐피리미딘의Phenylpyrimidine 합성 synthesis

Figure pat00013
Figure pat00013

4-([1,1'-바이페닐]-4-일)-6-(3,5-디브로모페닐)-2-페닐피리미딘 4 - ([1,1'-biphenyl] -4-yl) -6- (3,5-dibromophenyl) -2- phenylpyrimidine

50g(92.2mmol)과 피리딘-3-일보로닉 산 11.3g(92.2mmol)에 1,4-디옥산 250 mL를 가하였다. Pd(PPh3)4 5.32g(4.61mmol), K2CO3 31.85g(230mol)을 첨가 후 120에서 24시간 가열 환류하였다. 상온으로 온도를 냉각하고 반응액에 염화암모늄 수용액 500 mL로 반응을 종결시켰다. 혼합액을 M.C 500 mL로 추출한 후, 증류수로 세척하였다. 얻어진 유기층을 무수 MgSO4로 건조하고, 감압증류하고 실리카겔 컬럼크로마토그래피로 정제하여 목적 화합물 30g(수율 61%)을 얻었다. 1H-NMR: 9.24(s, 1H), 8.70(d, 1H), 8.42~8.30(m, 5H), 8.24(s, 1H), 7.85~7.77(m, 3H), 7.75(m, 2H); 7.55~7.41(m, 9H), HRMS [M]+: 540.46(92.2 mmol) of pyridine-3-ylboronic acid and 250 mL of 1,4-dioxane were added. 5.32 g (4.61 mmol) of Pd (PPh 3 ) 4 and 31.85 g (230 mol) of K 2 CO 3 were added, and the mixture was refluxed at 120 ° C. for 24 hours. The reaction solution was cooled to room temperature and the reaction was terminated with 500 mL of an aqueous ammonium chloride solution. The mixture was extracted with 500 mL of MC and then washed with distilled water. The obtained organic layer was dried over anhydrous MgSO 4 , distilled under reduced pressure, and purified by silica gel column chromatography to obtain 30 g of the target compound (yield: 61%). 1H-NMR: 9.24 (s, 1H), 8.70 (d, 1H), 8.42-8.30 (m, 5H), 8.24 (s, 1H), 7.85-7.77 (m, 3H), 7.75 7.55-7.41 (m, 9H), HRMS [M] < + & gt ; : 540.46

[[ 준비예Preparation Example 2] 2]

4-([1,1'-4 - ([1,1'- 바이페닐Biphenyl ]-4-일)-6-(3-] -4-yl) -6- (3- 브로모Bromo -5-(피리딘-4-일)페닐)-2--5- (pyridin-4-yl) phenyl) -2- 페닐피리미딘의Phenylpyrimidine 합성 synthesis

Figure pat00014
Figure pat00014

반응물로 피리딘-4-일보로닉 산을 사용한 것을 제외하고는 [준비예 1]과 동일한 과정을 수행하여 목적 화합물 26g을 얻었다; HRMS [M]+: 540.46The procedure of Preparation Example 1 was repeated except that pyridine-4-ylboronic acid was used as a reactant to obtain 26 g of the target compound; HRMS [M] < + >: 540.46

[[ 준비예Preparation Example 3] 3]

8-(3-(6-([1,1'-8- (3- (6 - ([1,1'- 바이페닐Biphenyl ]-4-일)-2-] -4-yl) -2- 페닐피리미딘Phenylpyrimidine -4-일)-5-Yl) -5- 브로모페닐Bromophenyl )퀴놀린의 합성) Quinoline

Figure pat00015
Figure pat00015

반응물로 퀴놀린-8-일보로닉 산을 사용한 것을 제외하고는 [준비예 1]과 동일한 과정을 수행하여 목적 화합물 31g을 얻었다; HRMS [M]+: 590.52The procedure of Preparation Example 1 was repeated except that quinolin-8-ylboronic acid was used as a reactant to obtain 31 g of the target compound; HRMS [M] < + >: 590.52

[[ 준비예Preparation Example 4] 4]

4-([1,1'-4 - ([1,1'- 바이페닐Biphenyl ]-4-일)-6-(5-] -4-yl) -6- (5- 브로모Bromo -4'-(피리딘-3-일)-[1,1'--4 '- (pyridin-3-yl) - [1,1'- 바이페닐Biphenyl ]-3-일)-2-페닐피리미딘의 합성] -3-yl) -2-phenylpyrimidine

Figure pat00016
Figure pat00016

반응물로 (4-(피리딘-3-일)페닐)보로닉 산을 사용한 것을 제외하고는 [준비예 1]과 동일한 과정을 수행하여 목적 화합물 35g을 얻었다; HRMS [M]+: 616.56The procedure of Preparation Example 1 was repeated except for using (4- (pyridin-3-yl) phenyl) boronic acid as a reactant to obtain 35 g of the target compound; HRMS [M] < + >: 616.56

[[ 준비예Preparation Example 5] 5]

2-(3-(6-([1,1'-2- (3- (6 - ([1,1'- 바이페닐Biphenyl ]-4-일)-2-] -4-yl) -2- 페닐피리미딘Phenylpyrimidine -4-일)-5-Yl) -5- 브로모페닐Bromophenyl )-1,10-페난트롤린의 합성) -1,10-phenanthroline Synthesis

Figure pat00017
Figure pat00017

반응물로 2-(4,4,5,5-테트라메틸-1,3,2-디옥사보로란-2-일)-1,10-페난트롤린을 사용한 것을 제외하고는 [준비예 1]과 동일한 과정을 수행하여 목적 화합물 31g을 얻었다; HRMS [M]+: 641.57Except that 2- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) -1,10-phenanthroline was used as a reactant in Preparation Example 1 ] To obtain 31 g of the target compound; HRMS [M] < + >: 641.57

[[ 준비예Preparation Example 6] 6]

4-([1,1'-4 - ([1,1'- 바이페닐Biphenyl ]-4-일)-6-(3-] -4-yl) -6- (3- 브로모Bromo -5-(피리딘-3-일)페닐)-2--5- (pyridin-3-yl) phenyl) -2- 페닐피리미딘의Phenylpyrimidine 합성 synthesis

Figure pat00018
Figure pat00018

반응물로 2-([1,1'-바이페닐]-4-일)-4-(3,5-디브로모페닐)-6-페닐-1,3,5-트리아진을 사용한 것을 제외하고는 [준비예 1]과 동일한 과정을 수행하여 목적 화합물 23g을 얻었다; HRMS [M]+: 541.45Except that 2 - ([1,1'-biphenyl] -4-yl) -4- (3,5-dibromophenyl) -6-phenyl-1,3,5-triazine was used as a reactant Was subjected to the same procedure as in [Preparation Example 1] to obtain 23 g of the target compound; HRMS [M] < + >: 541.45

[[ 준비예Preparation Example 7] 7]

4-([1,1'-4 - ([1,1'- 바이페닐Biphenyl ]-4-일)-6-(3-] -4-yl) -6- (3- 브로모Bromo -5-(피리딘-4-일)페닐)-2--5- (pyridin-4-yl) phenyl) -2- 페닐피리미딘의Phenylpyrimidine 합성 synthesis

Figure pat00019
Figure pat00019

반응물로 2-([1,1'-바이페닐]-4-일)-4-(3,5-디브로모페닐)-6-페닐-1,3,5-트리아진을 사용한 것을 제외하고는 [준비예 2]과 동일한 과정을 수행하여 목적 화합물 22g을 얻었다; HRMS [M]+: 541.45Except that 2 - ([1,1'-biphenyl] -4-yl) -4- (3,5-dibromophenyl) -6-phenyl-1,3,5-triazine was used as a reactant Was subjected to the same procedure as in [Preparation Example 2] to obtain 22 g of the target compound; HRMS [M] < + >: 541.45

[[ 준비예Preparation Example 8] 8]

8-(3-(6-([1,1'-8- (3- (6 - ([1,1'- 바이페닐Biphenyl ]-4-일)-2-] -4-yl) -2- 페닐피리미딘Phenylpyrimidine -4-일)-5-Yl) -5- 브로모페닐Bromophenyl )퀴놀린의 합성) Quinoline

Figure pat00020
Figure pat00020

반응물로 2-([1,1'-바이페닐]-4-일)-4-(3,5-디브로모페닐)-6-페닐-1,3,5-트리아진을 사용한 것을 제외하고는 [준비예 3]과 동일한 과정을 수행하여 목적 화합물 26g을 얻었다; HRMS [M]+: 591.51Except that 2 - ([1,1'-biphenyl] -4-yl) -4- (3,5-dibromophenyl) -6-phenyl-1,3,5-triazine was used as a reactant Was subjected to the same procedure as in [Preparation Example 3] to obtain 26 g of the target compound; HRMS [M] < + >: 591.51

[[ 준비예Preparation Example 9] 9]

4-([1,1'-4 - ([1,1'- 바이페닐Biphenyl ]-4-일)-6-(5-] -4-yl) -6- (5- 브로모Bromo -4'-(피리딘-3-일)-[1,1'--4 '- (pyridin-3-yl) - [1,1'- 바이페닐Biphenyl ]-3-일)-2-페닐피리미딘의 합성] -3-yl) -2-phenylpyrimidine

Figure pat00021
Figure pat00021

반응물로 2-([1,1'-바이페닐]-4-일)-4-(3,5-디브로모페닐)-6-페닐-1,3,5-트리아진을 사용한 것을 제외하고는 [준비예 4]과 동일한 과정을 수행하여 목적 화합물 29g을 얻었다; HRMS [M]+: 615.55Except that 2 - ([1,1'-biphenyl] -4-yl) -4- (3,5-dibromophenyl) -6-phenyl-1,3,5-triazine was used as a reactant Was carried out in the same manner as in [Preparation Example 4] to obtain 29 g of the target compound; HRMS [M] < + >: 615.55

[[ 준비예Preparation Example 10] 10]

2-(3-(6-([1,1'-2- (3- (6 - ([1,1'- 바이페닐Biphenyl ]-4-일)-2-] -4-yl) -2- 페닐피리미딘Phenylpyrimidine -4-일)-5-Yl) -5- 브로모페닐Bromophenyl )-1,10-페난트롤린의 합성) -1,10-phenanthroline Synthesis

Figure pat00022
Figure pat00022

반응물로 2-([1,1'-바이페닐]-4-일)-4-(3,5-디브로모페닐)-6-페닐-1,3,5-트리아진을 사용한 것을 제외하고는 [준비예 5]과 동일한 과정을 수행하여 목적 화합물 28g을 얻었다; HRMS [M]+: 640.56Except that 2 - ([1,1'-biphenyl] -4-yl) -4- (3,5-dibromophenyl) -6-phenyl-1,3,5-triazine was used as a reactant Was subjected to the same procedure as in [Preparation Example 5] to obtain 28 g of the desired compound; HRMS [M] < + >: 640.56

[[ 합성예Synthetic example 1] Mat 1의 합성 1] Synthesis of Mat 1

Figure pat00023
Figure pat00023

4-([1,1'-바이페닐]-4-일)-6-(3-브로모-5-(피리딘-3-일)페닐)-2-페닐피리미딘 5g(9.25mmol)과 페닐보로닉 산 1.24g(10.17mmol)에 1,4-디옥산 250 mL를 가하였다. Pd(PPh3)4 0.53g(0.46mmol), K2CO3 3.19g(23.1mol)을 첨가 후 120에서 24시간 가열환류하였다. 상온으로 온도를 냉각하고 반응액에 염화암모늄 수용액 500 mL로 반응을 종결시켰다. 혼합액을 M.C 200 mL로 추출한 후, 증류수로 세척하였다. 얻어진 유기층을 무수 MgSO4로 건조하고, 감압증류하고 실리카겔 컬럼크로마토그래피로 정제하여 목적 화합물 4.37g(수율 88%)을 얻었다. 1H-NMR: 9.24(s, 1H), 8.70(d, 1H), 8.42~8.30(m, 5H), 8.23(s, 1H), 8.04(s, 3H), 7.85(m, 2H), 7.75(m, 2H); 7.51~7.41(m, 10H), HRMS [M]+: 537.67(9.25 mmol) of 4 - ([1,1'-biphenyl] -4-yl) -6- (3-bromo-5- 250 mL of 1,4-dioxane was added to 1.24 g (10.17 mmol) of boronic acid. Pd (PPh 3) 4 0.53g ( 0.46mmol), K 2 CO 3 was added to 3.19g (23.1mol) was heated to reflux at 120 for 24 hours. The reaction solution was cooled to room temperature and the reaction was terminated with 500 mL of an aqueous ammonium chloride solution. The mixture was extracted with 200 mL of MC and then washed with distilled water. The obtained organic layer was dried over anhydrous MgSO 4 , distilled under reduced pressure, and purified by silica gel column chromatography to obtain 4.37 g (yield 88%) of the desired compound. (S, 3H), 7.85 (m, 2H), 7.75 (m, 2H), 8.24 (s, m, 2H); 7.51-7.41 (m, 10H), HRMS [M] < + & gt ; : 537.67

[[ 합성예Synthetic example 2] Mat 2의 합성 2] Synthesis of Mat 2

Figure pat00024
Figure pat00024

반응물로 나프탈렌-2-일보로닉 산을 사용한 것을 제외하고는 [합성예 1]과 동일한 과정을 수행하여 목적 화합물 5.1g을 얻었다; HRMS [M]+: 587.73The same procedure as in [Synthesis Example 1] was repeated except that naphthalene-2-ylboronic acid was used as a reactant, to obtain 5.1 g of the desired compound; HRMS [M] < + >: 587.73

[[ 합성예Synthetic example 3] Mat 3의 합성 3] Synthesis of Mat 3

Figure pat00025
Figure pat00025

반응물로 나프탈렌-1-일보로닉 산을 사용한 것을 제외하고는 [합성예 1]과 동일한 과정을 수행하여 목적 화합물 4.8g을 얻었다; HRMS [M]+: 587.73The same procedure as in [Synthesis Example 1] was carried out except that naphthalene-1-ylboronic acid was used as a reactant, to obtain 4.8 g of the desired compound; HRMS [M] < + >: 587.73

[[ 합성예Synthetic example 4] Mat 4의 합성 4] Synthesis of Mat 4

Figure pat00026
Figure pat00026

반응물로 페난트렌-9-일보로닉 산을 사용한 것을 제외하고는 [합성예 1]과 동일한 과정을 수행하여 목적 화합물 5.6g을 얻었다; HRMS [M]+: 637.79The same procedure as in [Synthesis Example 1] was conducted except that phenanthrene-9-ylboronic acid was used as a reactant, to obtain 5.6 g of the desired compound; HRMS [M] < + >: 637.79

[[ 합성예Synthetic example 5] Mat 5의 합성 5] Synthesis of Mat 5

Figure pat00027
Figure pat00027

반응물로 안트라센-9-일보로닉 산을 사용한 것을 제외하고는 [합성예 1]과 동일한 과정을 수행하여 목적 화합물 5.5g을 얻었다; HRMS [M]+: 637.79The same procedure as in [Synthesis Example 1] was conducted except that an anthracene-9-ylboronic acid was used as a reactant, to obtain 5.5 g of the desired compound; HRMS [M] < + >: 637.79

[[ 합성예Synthetic example 6] Mat 6의 합성 6] Synthesis of Mat 6

Figure pat00028
Figure pat00028

반응물로 (10-페닐안트라센-9-일)보로닉 산을 사용한 것을 제외하고는 [합성예 1]과 동일한 과정을 수행하여 목적 화합물 6.9g을 얻었다; HRMS [M]+: 713.88The procedure of Synthesis Example 1 was repeated except that (10-phenylanthracene-9-yl) boronic acid was used as a reactant, to obtain 6.9 g of the title compound; HRMS [M] < + >: 713.88

[[ 합성예Synthetic example 7] Mat 7의 합성 7] Synthesis of Mat 7

Figure pat00029
Figure pat00029

반응물로 트리페닐렌-2-일보로닉 산을 사용한 것을 제외하고는 [합성예 1]과 동일한 과정을 수행하여 목적 화합물 5.4g을 얻었다; HRMS [M]+: 687.85The same procedure as in [Synthesis Example 1] was conducted except that triphenylene-2-ylboronic acid was used as a reactant, to obtain 5.4 g of the title compound; HRMS [M] < + >: 687.85

[[ 합성예Synthetic example 8] Mat 8의 합성 8] Synthesis of Mat 8

Figure pat00030
Figure pat00030

반응물로 (3a1,6-디하이드로피렌-1-일)보로닉 산을 사용한 것을 제외하고는 [합성예 1]과 동일한 과정을 수행하여 목적 화합물 6.0g을 얻었다; HRMS [M]+: 661.81The same procedure as in [Synthesis Example 1] was repeated but using (3a1,6-dihydropyren-1-yl) boronic acid as a reactant, 6.0 g of the target compound was obtained; HRMS [M] < + >: 661.81

[[ 합성예Synthetic example 9] Mat 9의 합성 9] Synthesis of Mat 9

Figure pat00031
Figure pat00031

반응물로 (9,9-디메틸-9H-플로우렌-3-일)보로닉 산을 사용한 것을 제외하고는 [합성예 1]과 동일한 과정을 수행하여 목적 화합물 5.8g을 얻었다; HRMS [M]+: 653.83The same procedure as in [Synthesis Example 1] was repeated except for using (9,9-dimethyl-9H-flowen-3-yl) boronic acid as a reactant, to obtain 5.8 g of the desired compound; HRMS [M] < + >: 653.83

[[ 합성예Synthetic example 10] Mat 10의 합성 10] Synthesis of Mat 10

Figure pat00032
Figure pat00032

반응물로 (9-페닐-9H-카바졸-3-일)보로닉 산을 사용한 것을 제외하고는 [합성예 1]과 동일한 과정을 수행하여 목적 화합물 7g을 얻었다; HRMS [M]+: 702.86The same procedure as in [Synthesis Example 1] was repeated, except that (9-phenyl-9H-carbazol-3-yl) boronic acid was used as a reaction product to obtain 7 g of the target compound; HRMS [M] < + >: 702.86

[[ 합성예Synthetic example 11] Mat 11의 합성 11] Synthesis of Mat 11

Figure pat00033
Figure pat00033

반응물로 디벤조[b,d]퓨란-2-일보로닉 산을 사용한 것을 제외하고는 [합성예 1]과 동일한 과정을 수행하여 목적 화합물 5.6g을 얻었다; HRMS [M]+: 627.75The same procedure as in [Synthesis Example 1] was conducted except that dibenzo [b, d] furan-2-ylboronic acid was used as a reactant, to obtain 5.6 g of the desired compound; HRMS [M] < + >: 627.75

[[ 합성예Synthetic example 12] Mat 12의 합성 12] Synthesis of Mat 12

Figure pat00034
Figure pat00034

4-([1,1'-바이페닐]-4-일)-6-(3-브로모-5-(피리딘-3-일)페닐)-2-페닐피리미딘 5g(9.25mmol)과 카바졸 1.7g(10.17mmol)에 자일렌 250 mL를 가하였다. Pd2(dba)3 0.42g (0.46mmol), Xphos 0.44g(0.92mmol), NaOtBu 2.2g(23.1mol)을 첨가 후 120에서 24시간 가열환류하였다. 상온으로 온도를 냉각하고 반응액에 염화암모늄 수용액 500 mL로 반응을 종결시켰다. 혼합액을 M.C 500 mL로 추출한 후, 증류수로 세척하였다. 얻어진 유기층을 무수 MgSO4로 건조하고, 감압증류하고 실리카겔 컬럼크로마토그래피로 정제하여 목적 화합물 4.46g(수율 77%)을 얻었다. 1H-NMR: 9.24(s, 1H), 8.70(d, 1H), 8.55(d, 1H), 8.42~8.19(m, 9H), 7.9~7.85(m, 4H), 7.50~7.16(m, 12H); HRMS [M]+: 626.76(9.25 mmol) of 4 - ([1,1'-biphenyl] -4-yl) -6- (3-bromo-5- To 1.7 g (10.17 mmol) of the sol was added 250 mL of xylene. 0.42 g (0.46 mmol) of Pd 2 (dba) 3 , 0.44 g (0.92 mmol) of Xphos and 2.2 g (23.1 mol) of NaOtBu were added and the mixture was refluxed at 120 to 24 hours. The reaction solution was cooled to room temperature and the reaction was terminated with 500 mL of an aqueous ammonium chloride solution. The mixture was extracted with 500 mL of MC and then washed with distilled water. The obtained organic layer was dried over anhydrous MgSO 4 , distilled under reduced pressure, and purified by silica gel column chromatography to obtain 4.46 g (yield 77%) of the desired compound. (M, 4H), 7.50-7.16 (m, 12H (m, 2H), 7.42 ); HRMS [M] < + & gt ; : 626.76

[[ 합성예Synthetic example 13] Mat 13의 합성 13] Synthesis of Mat 13

Figure pat00035
Figure pat00035

반응물로 3-페닐-9H-카바졸을 사용한 것을 제외하고는 [합성예 12]과 동일한 과정을 수행하여 목적 화합물 5.9g을 얻었다; HRMS [M]+: 702.86The same procedure as in [Synthesis Example 12] was conducted except that 3-phenyl-9H-carbazole was used as a reactant, to obtain 5.9 g of the title compound; HRMS [M] < + >: 702.86

[[ 합성예Synthetic example 14] Mat 14의 합성 14] Synthesis of Mat 14

Figure pat00036
Figure pat00036

반응물로 2-(디벤조[b,e][1,4]디옥신-2-일)-4,4,5,5-테트라메틸-1,3,2-디옥사보로란을 사용한 것을 제외하고는 [합성예 1]과 동일한 과정을 수행하여 목적 화합물 6.1g을 얻었다; HRMS [M]+: 643.75(Dibenzo [b, e] [1,4] dioxin-2-yl) -4,4,5,5-tetramethyl-1,3,2-dioxaborolane was used as a reactant , The same procedure as in [Synthesis Example 1] was conducted to obtain 6.1 g of the desired compound; HRMS [M] < + >: 643.75

[[ 합성예Synthetic example 15] Mat 15의 합성 15] Synthesis of Mat 15

Figure pat00037
Figure pat00037

반응물로 10H-페녹사진을 사용한 것을 제외하고는 [합성예 12]과 동일한 과정을 수행하여 목적 화합물 5.2g을 얻었다; HRMS [M]+: 642.76The same procedure as in [Synthesis Example 12] was conducted except that 10H-phenoxazine was used as a reactant, to obtain 5.2 g of the target compound; HRMS [M] < + >: 642.76

[[ 합성예Synthetic example 16] Mat 16의 합성 16] Synthesis of Mat 16

Figure pat00038
Figure pat00038

반응물로 2-(4,4,5,5-테트라메틸-1,3,2-디옥사보로란-2-일)-1,10-페난트롤린을 사용한 것을 제외하고는 [합성예 1]과 동일한 과정을 수행하여 목적 화합물 4.3g을 얻었다; HRMS [M]+: 639.76Except that 2- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) -1,10-phenanthroline was used as a reactant in Synthesis Example 1 ] To obtain the desired compound (4.3 g); HRMS [M] < + >: 639.76

[[ 합성예Synthetic example 17] Mat 17의 합성 17] Synthesis of Mat 17

Figure pat00039
Figure pat00039

반응물로 퀴놀린-8-일보로닉 산을 사용한 것을 제외하고는 [합성예 1]과 동일한 과정을 수행하여 목적 화합물 5.0g을 얻었다; HRMS [M]+: 588.71The same procedure as in [Synthesis Example 1] was repeated except that quinolin-8-ylboronic acid was used as a reactant, to obtain 5.0 g of the target compound; HRMS [M] < + >: 588.71

[[ 합성예Synthetic example 18] Mat 18의 합성 18] Synthesis of Mat 18

Figure pat00040
Figure pat00040

반응물로 (4-(피리딘-3-일)페닐)보로닉 산을 사용한 것을 제외하고는 [합성예 1]과 동일한 과정을 수행하여 목적 화합물 6.5g을 얻었다; HRMS [M]+: 614.75The same procedure as in [Synthesis Example 1] was conducted except that 4- (pyridin-3-yl) phenyl) boronic acid was used as a reactant to obtain 6.5 g of the desired compound; HRMS [M] < + >: 614.75

[[ 합성예Synthetic example 19] Mat 19의 합성 19] Synthesis of Mat 19

Figure pat00041
Figure pat00041

반응물로 4-([1,1'-바이페닐]-4-일)-6-(3-브로모-5-(피리딘-4-일)페닐)-2-페닐피리미딘을 사용한 것을 제외하고는 [합성예 1]과 동일한 과정을 수행하여 목적 화합물 3.2g을 얻었다; HRMS [M]+: 537.67Except that 4 - ([1,1'-biphenyl] -4-yl) -6- (3-bromo-5- (pyridin-4-yl) phenyl) -2- phenylpyrimidine was used as a reactant Was carried out in the same manner as in [Synthesis Example 1] to obtain 3.2 g of the target compound; HRMS [M] < + >: 537.67

[[ 합성예Synthetic example 20] Mat 20의 합성 20] Synthesis of Mat 20

Figure pat00042
Figure pat00042

반응물로 4-([1,1'-바이페닐]-4-일)-6-(3-브로모-5-(피리딘-4-일)페닐)-2-페닐피리미딘을 사용한 것을 제외하고는 [합성예 2]과 동일한 과정을 수행하여 목적 화합물 2.8g을 얻었다; HRMS [M]+: 587.73Except that 4 - ([1,1'-biphenyl] -4-yl) -6- (3-bromo-5- (pyridin-4-yl) phenyl) -2- phenylpyrimidine was used as a reactant Was carried out in the same manner as in [Synthesis Example 2] to obtain 2.8 g of the desired compound; HRMS [M] < + >: 587.73

[[ 합성예Synthetic example 21] Mat 21의 합성 21] Synthesis of Mat 21

Figure pat00043
Figure pat00043

반응물로 4-([1,1'-바이페닐]-4-일)-6-(3-브로모-5-(피리딘-4-일)페닐)-2-페닐피리미딘을 사용한 것을 제외하고는 [합성예 3]과 동일한 과정을 수행하여 목적 화합물 3.2g을 얻었다; HRMS [M]+: 587.73Except that 4 - ([1,1'-biphenyl] -4-yl) -6- (3-bromo-5- (pyridin-4-yl) phenyl) -2- phenylpyrimidine was used as a reactant Was carried out in the same manner as in [Synthesis Example 3] to obtain 3.2 g of the desired compound; HRMS [M] < + >: 587.73

[[ 합성예Synthetic example 22] Mat 22의 합성 22] Synthesis of Mat 22

Figure pat00044
Figure pat00044

반응물로 4-([1,1'-바이페닐]-4-일)-6-(3-브로모-5-(피리딘-4-일)페닐)-2-페닐피리미딘을 사용한 것을 제외하고는 [합성예 4]과 동일한 과정을 수행하여 목적 화합물 3.0g을 얻었다; HRMS [M]+: 637.79Except that 4 - ([1,1'-biphenyl] -4-yl) -6- (3-bromo-5- (pyridin-4-yl) phenyl) -2- phenylpyrimidine was used as a reactant Was carried out in the same manner as in [Synthesis Example 4] to obtain 3.0 g of the target compound; HRMS [M] < + >: 637.79

[[ 합성예Synthetic example 23] Mat 23의 합성 23] Synthesis of Mat 23

Figure pat00045
Figure pat00045

반응물로 4-([1,1'-바이페닐]-4-일)-6-(3-브로모-5-(피리딘-4-일)페닐)-2-페닐피리미딘을 사용한 것을 제외하고는 [합성예 5]과 동일한 과정을 수행하여 목적 화합물 4.2g을 얻었다; HRMS [M]+: 637.79Except that 4 - ([1,1'-biphenyl] -4-yl) -6- (3-bromo-5- (pyridin-4-yl) phenyl) -2- phenylpyrimidine was used as a reactant Was subjected to the same procedure as in [Synthesis Example 5] to obtain 4.2 g of the target compound; HRMS [M] < + >: 637.79

[[ 합성예Synthetic example 24] Mat 24의 합성 24] Synthesis of Mat 24

Figure pat00046
Figure pat00046

반응물로 4-([1,1'-바이페닐]-4-일)-6-(3-브로모-5-(피리딘-4-일)페닐)-2-페닐피리미딘을 사용한 것을 제외하고는 [합성예 6]과 동일한 과정을 수행하여 목적 화합물 5.2g을 얻었다; HRMS [M]+: 713.88Except that 4 - ([1,1'-biphenyl] -4-yl) -6- (3-bromo-5- (pyridin-4-yl) phenyl) -2- phenylpyrimidine was used as a reactant Was carried out in the same manner as in [Synthesis Example 6] to obtain 5.2 g of the desired compound; HRMS [M] < + >: 713.88

[[ 합성예Synthetic example 25] Mat 25의 합성 25] Synthesis of Mat 25

Figure pat00047
Figure pat00047

반응물로 4-([1,1'-바이페닐]-4-일)-6-(3-브로모-5-(피리딘-4-일)페닐)-2-페닐피리미딘을 사용한 것을 제외하고는 [합성예 7]과 동일한 과정을 수행하여 목적 화합물 4.8g을 얻었다; HRMS [M]+: 687.85Except that 4 - ([1,1'-biphenyl] -4-yl) -6- (3-bromo-5- (pyridin-4-yl) phenyl) -2- phenylpyrimidine was used as a reactant Was carried out in the same manner as in [Synthesis Example 7] to obtain 4.8 g of the desired compound; HRMS [M] < + >: 687.85

[[ 합성예Synthetic example 26] Mat 26의 합성 26] Synthesis of Mat 26

Figure pat00048
Figure pat00048

반응물로 4-([1,1'-바이페닐]-4-일)-6-(3-브로모-5-(피리딘-4-일)페닐)-2-페닐피리미딘을 사용한 것을 제외하고는 [합성예 8]과 동일한 과정을 수행하여 목적 화합물 3.3g을 얻었다; HRMS [M]+: 661.81Except that 4 - ([1,1'-biphenyl] -4-yl) -6- (3-bromo-5- (pyridin-4-yl) phenyl) -2- phenylpyrimidine was used as a reactant Was subjected to the same procedure as in [Synthesis Example 8] to obtain 3.3 g of the target compound; HRMS [M] < + >: 661.81

[[ 합성예Synthetic example 27] Mat 27의 합성 27] Synthesis of Mat 27

Figure pat00049
Figure pat00049

반응물로 4-([1,1'-바이페닐]-4-일)-6-(3-브로모-5-(피리딘-4-일)페닐)-2-페닐피리미딘을 사용한 것을 제외하고는 [합성예 9]과 동일한 과정을 수행하여 목적 화합물 4.6g을 얻었다; HRMS [M]+: 653.83Except that 4 - ([1,1'-biphenyl] -4-yl) -6- (3-bromo-5- (pyridin-4-yl) phenyl) -2- phenylpyrimidine was used as a reactant Was carried out in the same manner as in [Synthesis Example 9] to obtain 4.6 g of the desired compound; HRMS [M] < + >: 653.83

[[ 합성예Synthetic example 28] Mat 28의 합성 28] Synthesis of Mat 28

Figure pat00050
Figure pat00050

반응물로 4-([1,1'-바이페닐]-4-일)-6-(3-브로모-5-(피리딘-4-일)페닐)-2-페닐피리미딘을 사용한 것을 제외하고는 [합성예 10]과 동일한 과정을 수행하여 목적 화합물 4.3g을 얻었다; HRMS [M]+: 702.86Except that 4 - ([1,1'-biphenyl] -4-yl) -6- (3-bromo-5- (pyridin-4-yl) phenyl) -2- phenylpyrimidine was used as a reactant Was subjected to the same procedure as in [Synthesis Example 10] to obtain 4.3 g of the target compound; HRMS [M] < + >: 702.86

[[ 합성예Synthetic example 29] Mat 29의 합성 29] Synthesis of Mat 29

Figure pat00051
Figure pat00051

반응물로 4-([1,1'-바이페닐]-4-일)-6-(3-브로모-5-(피리딘-4-일)페닐)-2-페닐피리미딘을 사용한 것을 제외하고는 [합성예 11]과 동일한 과정을 수행하여 목적 화합물 3.3g을 얻었다; HRMS [M]+: 627.75Except that 4 - ([1,1'-biphenyl] -4-yl) -6- (3-bromo-5- (pyridin-4-yl) phenyl) -2- phenylpyrimidine was used as a reactant Was subjected to the same procedure as in [Synthesis Example 11] to obtain 3.3 g of the target compound; HRMS [M] < + >: 627.75

[[ 합성예Synthetic example 30] Mat 30의 합성 30] Synthesis of Mat 30

Figure pat00052
Figure pat00052

반응물로 4-([1,1'-바이페닐]-4-일)-6-(3-브로모-5-(피리딘-4-일)페닐)-2-페닐피리미딘을 사용한 것을 제외하고는 [합성예 12]과 동일한 과정을 수행하여 목적 화합물 2.5g을 얻었다; HRMS [M]+: 626.76Except that 4 - ([1,1'-biphenyl] -4-yl) -6- (3-bromo-5- (pyridin-4-yl) phenyl) -2- phenylpyrimidine was used as a reactant Was subjected to the same procedure as in [Synthesis Example 12] to obtain 2.5 g of the desired compound; HRMS [M] < + >: 626.76

[[ 합성예Synthetic example 31] Mat 31의 합성 31] Synthesis of Mat 31

Figure pat00053
Figure pat00053

반응물로 4-([1,1'-바이페닐]-4-일)-6-(3-브로모-5-(피리딘-4-일)페닐)-2-페닐피리미딘을 사용한 것을 제외하고는 [합성예 13]과 동일한 과정을 수행하여 목적 화합물 2.8g을 얻었다; HRMS [M]+: 702.86Except that 4 - ([1,1'-biphenyl] -4-yl) -6- (3-bromo-5- (pyridin-4-yl) phenyl) -2- phenylpyrimidine was used as a reactant Was carried out in the same manner as in [Synthesis Example 13] to obtain the objective compound (2.8 g); HRMS [M] < + >: 702.86

[[ 합성예Synthetic example 32] Mat 32의 합성 32] Synthesis of Mat 32

Figure pat00054
Figure pat00054

반응물로 4-([1,1'-바이페닐]-4-일)-6-(3-브로모-5-(피리딘-4-일)페닐)-2-페닐피리미딘을 사용한 것을 제외하고는 [합성예 14]과 동일한 과정을 수행하여 목적 화합물 2.1g을 얻었다; HRMS [M]+: 643.75Except that 4 - ([1,1'-biphenyl] -4-yl) -6- (3-bromo-5- (pyridin-4-yl) phenyl) -2- phenylpyrimidine was used as a reactant Was subjected to the same procedure as in [Synthesis Example 14] to obtain 2.1 g of the desired compound; HRMS [M] < + >: 643.75

[[ 합성예Synthetic example 33] Mat 33의 합성 33] Synthesis of Mat 33

Figure pat00055
Figure pat00055

반응물로 4-([1,1'-바이페닐]-4-일)-6-(3-브로모-5-(피리딘-4-일)페닐)-2-페닐피리미딘을 사용한 것을 제외하고는 [합성예 15]과 동일한 과정을 수행하여 목적 화합물 1.6g을 얻었다; HRMS [M]+: 642.76Except that 4 - ([1,1'-biphenyl] -4-yl) -6- (3-bromo-5- (pyridin-4-yl) phenyl) -2- phenylpyrimidine was used as a reactant Was subjected to the same procedure as in [Synthesis Example 15] to obtain 1.6 g of the desired compound; HRMS [M] < + >: 642.76

[[ 합성예Synthetic example 34] Mat 34의 합성 34] Synthesis of Mat 34

Figure pat00056
Figure pat00056

반응물로 4-([1,1'-바이페닐]-4-일)-6-(3-브로모-5-(피리딘-4-일)페닐)-2-페닐피리미딘을 사용한 것을 제외하고는 [합성예 16]과 동일한 과정을 수행하여 목적 화합물 3.0g을 얻었다; HRMS [M]+: 639.76Except that 4 - ([1,1'-biphenyl] -4-yl) -6- (3-bromo-5- (pyridin-4-yl) phenyl) -2- phenylpyrimidine was used as a reactant Was subjected to the same procedure as in [Synthesis Example 16] to obtain 3.0 g of the target compound; HRMS [M] < + >: 639.76

[[ 합성예Synthetic example 35] Mat 35의 합성 35] Synthesis of Mat 35

Figure pat00057
Figure pat00057

반응물로 4-([1,1'-바이페닐]-4-일)-6-(3-브로모-5-(피리딘-4-일)페닐)-2-페닐피리미딘을 사용한 것을 제외하고는 [합성예 17]과 동일한 과정을 수행하여 목적 화합물 3.6g을 얻었다; HRMS [M]+: 588.71Except that 4 - ([1,1'-biphenyl] -4-yl) -6- (3-bromo-5- (pyridin-4-yl) phenyl) -2- phenylpyrimidine was used as a reactant Was subjected to the same procedure as in [Synthesis Example 17] to obtain 3.6 g of the desired compound; HRMS [M] < + >: 588.71

[[ 합성예Synthetic example 36] Mat 36의 합성 36] Synthesis of Mat 36

Figure pat00058
Figure pat00058

반응물로 4-([1,1'-바이페닐]-4-일)-6-(3-브로모-5-(피리딘-4-일)페닐)-2-페닐피리미딘을 사용한 것을 제외하고는 [합성예 18]과 동일한 과정을 수행하여 목적 화합물 3.7g을 얻었다; HRMS [M]+: 614.75Except that 4 - ([1,1'-biphenyl] -4-yl) -6- (3-bromo-5- (pyridin-4-yl) phenyl) -2- phenylpyrimidine was used as a reactant Was obtained in the same manner as in [Synthesis Example 18], 3.7 g of the desired compound; HRMS [M] < + >: 614.75

[[ 합성예Synthetic example 37] Mat 37의 합성 37] Synthesis of Mat 37

Figure pat00059
Figure pat00059

반응물로 8-(3-(6-([1,1'-바이페닐]-4-일)-2-페닐피리미딘-4-일)-5-브로모페닐)퀴놀린을 사용한 것을 제외하고는 [합성예 1]과 동일한 과정을 수행하여 목적 화합물 4.5g을 얻었다; HRMS [M]+: 587.73Except that 8- (3- (6 - ([1,1'-biphenyl] -4-yl) -2-phenylpyrimidin-4-yl) -5-bromophenyl) quinoline was used as a reactant The same procedure as in [Synthesis Example 1] was conducted to obtain 4.5 g of the target compound; HRMS [M] < + >: 587.73

[[ 합성예Synthetic example 38] Mat 38의 합성 38] Synthesis of Mat 38

Figure pat00060
Figure pat00060

반응물로 8-(3-(6-([1,1'-바이페닐]-4-일)-2-페닐피리미딘-4-일)-5-브로모페닐)퀴놀린을 사용한 것을 제외하고는 [합성예 2]과 동일한 과정을 수행하여 목적 화합물 4.3g을 얻었다; HRMS [M]+: 637.79Except that 8- (3- (6 - ([1,1'-biphenyl] -4-yl) -2-phenylpyrimidin-4-yl) -5-bromophenyl) quinoline was used as a reactant The same procedure as in [Synthesis Example 2] was conducted to obtain 4.3 g of the objective compound; HRMS [M] < + >: 637.79

[[ 합성예Synthetic example 39] Mat 39의 합성 39] Synthesis of Mat 39

Figure pat00061
Figure pat00061

반응물로 8-(3-(6-([1,1'-바이페닐]-4-일)-2-페닐피리미딘-4-일)-5-브로모페닐)퀴놀린을 사용한 것을 제외하고는 [합성예 3]과 동일한 과정을 수행하여 목적 화합물 3.8g을 얻었다; HRMS [M]+: 637.79Except that 8- (3- (6 - ([1,1'-biphenyl] -4-yl) -2-phenylpyrimidin-4-yl) -5-bromophenyl) quinoline was used as a reactant The same procedure as in [Synthesis Example 3] was conducted to obtain 3.8 g of the target compound; HRMS [M] < + >: 637.79

[[ 합성예Synthetic example 40] Mat 40의 합성 40] Synthesis of Mat 40

Figure pat00062
Figure pat00062

반응물로 8-(3-(6-([1,1'-바이페닐]-4-일)-2-페닐피리미딘-4-일)-5-브로모페닐)퀴놀린을 사용한 것을 제외하고는 [합성예 4]과 동일한 과정을 수행하여 목적 화합물 4.9g을 얻었다; HRMS [M]+: 687.85Except that 8- (3- (6 - ([1,1'-biphenyl] -4-yl) -2-phenylpyrimidin-4-yl) -5-bromophenyl) quinoline was used as a reactant [Synthesis Example 4] was carried out to obtain 4.9 g of the desired compound; HRMS [M] < + >: 687.85

[[ 합성예Synthetic example 41] Mat 41의 합성 41] Synthesis of Mat 41

Figure pat00063
Figure pat00063

반응물로 8-(3-(6-([1,1'-바이페닐]-4-일)-2-페닐피리미딘-4-일)-5-브로모페닐)퀴놀린을 사용한 것을 제외하고는 [합성예 5]과 동일한 과정을 수행하여 목적 화합물 4.8g을 얻었다; HRMS [M]+: 687.85Except that 8- (3- (6 - ([1,1'-biphenyl] -4-yl) -2-phenylpyrimidin-4-yl) -5-bromophenyl) quinoline was used as a reactant [Synthesis Example 5] was carried out to obtain 4.8 g of the target compound; HRMS [M] < + >: 687.85

[[ 합성예Synthetic example 42] Mat 42의 합성 42] Synthesis of Mat 42

Figure pat00064
Figure pat00064

반응물로 8-(3-(6-([1,1'-바이페닐]-4-일)-2-페닐피리미딘-4-일)-5-브로모페닐)퀴놀린을 사용한 것을 제외하고는 [합성예 6]과 동일한 과정을 수행하여 목적 화합물 5.1g을 얻었다; HRMS [M]+: 763.94Except that 8- (3- (6 - ([1,1'-biphenyl] -4-yl) -2-phenylpyrimidin-4-yl) -5-bromophenyl) quinoline was used as a reactant The same procedure as in [Synthesis Example 6] was conducted to obtain the desired compound (5.1 g; HRMS [M] < + >: 763.94

[[ 합성예Synthetic example 43] Mat 43의 합성 43] Synthesis of Mat 43

Figure pat00065
Figure pat00065

반응물로 8-(3-(6-([1,1'-바이페닐]-4-일)-2-페닐피리미딘-4-일)-5-브로모페닐)퀴놀린을 사용한 것을 제외하고는 [합성예 7]과 동일한 과정을 수행하여 목적 화합물 4.7g을 얻었다; HRMS [M]+: 737.91Except that 8- (3- (6 - ([1,1'-biphenyl] -4-yl) -2-phenylpyrimidin-4-yl) -5-bromophenyl) quinoline was used as a reactant [Synthesis Example 7] was carried out to obtain 4.7 g of the target compound; HRMS [M] < + >: 737.91

[[ 합성예Synthetic example 44] Mat 44의 합성 44] Synthesis of Mat 44

Figure pat00066
Figure pat00066

반응물로 8-(3-(6-([1,1'-바이페닐]-4-일)-2-페닐피리미딘-4-일)-5-브로모페닐)퀴놀린을 사용한 것을 제외하고는 [합성예 8]과 동일한 과정을 수행하여 목적 화합물 6.0g을 얻었다; HRMS [M]+: 711.87Except that 8- (3- (6 - ([1,1'-biphenyl] -4-yl) -2-phenylpyrimidin-4-yl) -5-bromophenyl) quinoline was used as a reactant [Synthesis Example 8] was carried out to obtain 6.0 g of the target compound; HRMS [M] < + >: 711.87

[[ 합성예Synthetic example 45] Mat 45의 합성 45] Synthesis of Mat 45

Figure pat00067
Figure pat00067

반응물로 8-(3-(6-([1,1'-바이페닐]-4-일)-2-페닐피리미딘-4-일)-5-브로모페닐)퀴놀린을 사용한 것을 제외하고는 [합성예 9]과 동일한 과정을 수행하여 목적 화합물 5.3g을 얻었다; HRMS [M]+: 703.89Except that 8- (3- (6 - ([1,1'-biphenyl] -4-yl) -2-phenylpyrimidin-4-yl) -5-bromophenyl) quinoline was used as a reactant [Synthesis Example 9] was carried out to obtain 5.3 g of the target compound; HRMS [M] < + >: 703.89

[[ 합성예Synthetic example 46] Mat 46의 합성 46] Synthesis of Mat 46

Figure pat00068
Figure pat00068

반응물로 8-(3-(6-([1,1'-바이페닐]-4-일)-2-페닐피리미딘-4-일)-5-브로모페닐)퀴놀린을 사용한 것을 제외하고는 [합성예 10]과 동일한 과정을 수행하여 목적 화합물 4.9g을 얻었다; HRMS [M]+: 752.92Except that 8- (3- (6 - ([1,1'-biphenyl] -4-yl) -2-phenylpyrimidin-4-yl) -5-bromophenyl) quinoline was used as a reactant [Synthesis Example 10] was carried out to obtain 4.9 g of the desired compound; HRMS [M] < + >: 752.92

[[ 합성예Synthetic example 47] Mat 47의 합성 47] Synthesis of Mat 47

Figure pat00069
Figure pat00069

반응물로 8-(3-(6-([1,1'-바이페닐]-4-일)-2-페닐피리미딘-4-일)-5-브로모페닐)퀴놀린을 사용한 것을 제외하고는 [합성예 11]과 동일한 과정을 수행하여 목적 화합물 3.8g을 얻었다; HRMS [M]+: 677.81Except that 8- (3- (6 - ([1,1'-biphenyl] -4-yl) -2-phenylpyrimidin-4-yl) -5-bromophenyl) quinoline was used as a reactant The same procedure as in [Synthesis Example 11] was conducted to obtain 3.8 g of the objective compound; HRMS [M] < + >: 677.81

[[ 합성예Synthetic example 48] Mat 48의 합성 48] Synthesis of Mat 48

Figure pat00070
Figure pat00070

반응물로 8-(3-(6-([1,1'-바이페닐]-4-일)-2-페닐피리미딘-4-일)-5-브로모페닐)퀴놀린을 사용한 것을 제외하고는 [합성예 12]과 동일한 과정을 수행하여 목적 화합물 3.6g을 얻었다; HRMS [M]+: 676.82Except that 8- (3- (6 - ([1,1'-biphenyl] -4-yl) -2-phenylpyrimidin-4-yl) -5-bromophenyl) quinoline was used as a reactant The same procedure as in [Synthesis Example 12] was conducted to obtain 3.6 g of the target compound; HRMS [M] < + >: 676.82

[[ 합성예Synthetic example 49 Mat 49의 합성 49 Synthesis of Mat 49

Figure pat00071
Figure pat00071

반응물로 8-(3-(6-([1,1'-바이페닐]-4-일)-2-페닐피리미딘-4-일)-5-브로모페닐)퀴놀린을 사용한 것을 제외하고는 [합성예 13]과 동일한 과정을 수행하여 목적 화합물 4.0g을 얻었다; HRMS [M]+: 752.92Except that 8- (3- (6 - ([1,1'-biphenyl] -4-yl) -2-phenylpyrimidin-4-yl) -5-bromophenyl) quinoline was used as a reactant The same procedure as in [Synthesis Example 13] was conducted to obtain 4.0 g of the target compound; HRMS [M] < + >: 752.92

[[ 합성예Synthetic example 50] Mat 50의 합성 50] Synthesis of Mat 50

Figure pat00072
Figure pat00072

반응물로 8-(3-(6-([1,1'-바이페닐]-4-일)-2-페닐피리미딘-4-일)-5-브로모페닐)퀴놀린을 사용한 것을 제외하고는 [합성예 14]과 동일한 과정을 수행하여 목적 화합물 3.2g을 얻었다; HRMS [M]+: 693.81Except that 8- (3- (6 - ([1,1'-biphenyl] -4-yl) -2-phenylpyrimidin-4-yl) -5-bromophenyl) quinoline was used as a reactant The same procedure as in [Synthesis Example 14] was conducted to obtain 3.2 g of the target compound; HRMS [M] < + >: 693.81

[[ 합성예Synthetic example 51] Mat 51의 합성 51] Synthesis of Mat 51

Figure pat00073
Figure pat00073

반응물로 8-(3-(6-([1,1'-바이페닐]-4-일)-2-페닐피리미딘-4-일)-5-브로모페닐)퀴놀린을 사용한 것을 제외하고는 [합성예 15]과 동일한 과정을 수행하여 목적 화합물 2.7g을 얻었다; HRMS [M]+: 692.82Except that 8- (3- (6 - ([1,1'-biphenyl] -4-yl) -2-phenylpyrimidin-4-yl) -5-bromophenyl) quinoline was used as a reactant The same procedure as in [Synthesis Example 15] was conducted to obtain 2.7 g of the target compound; HRMS [M] < + >: 692.82

[[ 합성예Synthetic example 52] Mat 52의 합성 52] Synthesis of Mat 52

Figure pat00074
Figure pat00074

반응물로 8-(3-(6-([1,1'-바이페닐]-4-일)-2-페닐피리미딘-4-일)-5-브로모페닐)퀴놀린을 사용한 것을 제외하고는 [합성예 16]과 동일한 과정을 수행하여 목적 화합물 3.0g을 얻었다; HRMS [M]+: 689.82Except that 8- (3- (6 - ([1,1'-biphenyl] -4-yl) -2-phenylpyrimidin-4-yl) -5-bromophenyl) quinoline was used as a reactant The procedure of Synthesis Example 16 was repeated to obtain 3.0 g of the target compound; HRMS [M] < + >: 689.82

[[ 합성예Synthetic example 53] Mat 53의 합성 53] Synthesis of Mat 53

Figure pat00075
Figure pat00075

반응물로 8-(3-(6-([1,1'-바이페닐]-4-일)-2-페닐피리미딘-4-일)-5-브로모페닐)퀴놀린을 사용한 것을 제외하고는 [합성예 18]과 동일한 과정을 수행하여 목적 화합물 3.1g을 얻었다; HRMS [M]+: 664.81Except that 8- (3- (6 - ([1,1'-biphenyl] -4-yl) -2-phenylpyrimidin-4-yl) -5-bromophenyl) quinoline was used as a reactant The procedure of Synthesis Example 18 was followed to obtain 3.1 g of the target compound; HRMS [M] < + >: 664.81

[[ 합성예Synthetic example 54] Mat 54의 합성 54] Synthesis of Mat 54

Figure pat00076
Figure pat00076

반응물로 4-([1,1'-바이페닐]-4-일)-6-(5-브로모-4'-(피리딘-3-일)-[1,1'-바이페닐]-3-일)-2-페닐피리미딘을 사용한 것을 제외하고는 [합성예 1]과 동일한 과정을 수행하여 목적 화합물 5.5g을 얻었다; HRMS [M]+: 613.76The reaction was carried out using 4 - ([1,1'-biphenyl] -4-yl) -6- (5-bromo-4 ' -Yl) -2-phenylpyrimidine was used in place of 2-bromo-4-methylpyridine, 5.5 g of the title compound was obtained by carrying out the same processes as in [Synthesis Example 1]; HRMS [M] < + >: 613.76

[[ 합성예Synthetic example 55] Mat 55의 합성 55] Synthesis of Mat 55

Figure pat00077
Figure pat00077

반응물로 4-([1,1'-바이페닐]-4-일)-6-(5-브로모-4'-(피리딘-3-일)-[1,1'-바이페닐]-3-일)-2-페닐피리미딘을 사용한 것을 제외하고는 [합성예 2]과 동일한 과정을 수행하여 목적 화합물 5.8g을 얻었다; HRMS [M]+: 663.82The reaction was carried out using 4 - ([1,1'-biphenyl] -4-yl) -6- (5-bromo-4 ' -Yl) -2-phenylpyrimidine was used in place of 2-chloro-4-fluorobenzaldehyde, the procedure of Synthetic Example 2 was repeated to give the desired compound (5.8 g; HRMS [M] < + >: 663.82

[[ 합성예Synthetic example 56] Mat 56의 합성 56] Synthesis of Mat 56

Figure pat00078
Figure pat00078

반응물로 4-([1,1'-바이페닐]-4-일)-6-(5-브로모-4'-(피리딘-3-일)-[1,1'-바이페닐]-3-일)-2-페닐피리미딘을 사용한 것을 제외하고는 [합성예 3]과 동일한 과정을 수행하여 목적 화합물 5.1g을 얻었다; HRMS [M]+: 663.82The reaction was carried out using 4 - ([1,1'-biphenyl] -4-yl) -6- (5-bromo-4 ' - yl) -2-phenylpyrimidine was used in place of 2-chloro-4-fluorobenzaldehyde, the procedure of Synthesis Example 3 was repeated to obtain the desired compound (5.1 g; HRMS [M] < + >: 663.82

[[ 합성예Synthetic example 57] Mat 57의 합성 57] Synthesis of Mat 57

Figure pat00079
Figure pat00079

반응물로 4-([1,1'-바이페닐]-4-일)-6-(5-브로모-4'-(피리딘-3-일)-[1,1'-바이페닐]-3-일)-2-페닐피리미딘을 사용한 것을 제외하고는 [합성예 4]과 동일한 과정을 수행하여 목적 화합물 6.7g을 얻었다; HRMS [M]+: 713.88The reaction was carried out using 4 - ([1,1'-biphenyl] -4-yl) -6- (5-bromo-4 ' - yl) -2-phenylpyrimidine was used in place of 2-chloro-4-methoxybenzaldehyde, the procedure of Synthetic Example 4 was repeated to give the desired compound (6.7 g; HRMS [M] < + >: 713.88

[[ 합성예Synthetic example 58] Mat 58의 합성 58] Synthesis of Mat 58

Figure pat00080
Figure pat00080

반응물로 4-([1,1'-바이페닐]-4-일)-6-(5-브로모-4'-(피리딘-3-일)-[1,1'-바이페닐]-3-일)-2-페닐피리미딘을 사용한 것을 제외하고는 [합성예 5]과 동일한 과정을 수행하여 목적 화합물 6.1g을 얻었다; HRMS [M]+: 713.88The reaction was carried out using 4 - ([1,1'-biphenyl] -4-yl) -6- (5-bromo-4 ' -Yl) -2-phenylpyrimidine was used in place of 2-bromo-2-methylpyridine, 6.1 g of the title compound was obtained by carrying out the same processes as in [Synthesis Example 5]; HRMS [M] < + >: 713.88

[[ 합성예Synthetic example 59] Mat 59의 합성 59] Synthesis of Mat 59

Figure pat00081
Figure pat00081

반응물로 4-([1,1'-바이페닐]-4-일)-6-(5-브로모-4'-(피리딘-3-일)-[1,1'-바이페닐]-3-일)-2-페닐피리미딘을 사용한 것을 제외하고는 [합성예 6]과 동일한 과정을 수행하여 목적 화합물 6.6g을 얻었다; HRMS [M]+: 789.98The reaction was carried out using 4 - ([1,1'-biphenyl] -4-yl) -6- (5-bromo-4 ' -Yl) -2-phenylpyrimidine was used in place of 2-chloro-4-fluorobenzyl chloride, the procedure of Synthesis Example 6 was repeated to obtain 6.6 g of the desired compound; HRMS [M] < + >: 789.98

[[ 합성예Synthetic example 60] Mat 60의 합성 60] Synthesis of Mat 60

Figure pat00082
Figure pat00082

반응물로 4-([1,1'-바이페닐]-4-일)-6-(5-브로모-4'-(피리딘-3-일)-[1,1'-바이페닐]-3-일)-2-페닐피리미딘을 사용한 것을 제외하고는 [합성예 7]과 동일한 과정을 수행하여 목적 화합물 6.0g을 얻었다; HRMS [M]+: 763.94The reaction was carried out using 4 - ([1,1'-biphenyl] -4-yl) -6- (5-bromo-4 ' -Yl) -2-phenylpyrimidine was used in place of 2-bromo-2-methylpyridine, the procedure of Synthesis Example 7 was repeated to obtain 6.0 g of the target compound; HRMS [M] < + >: 763.94

[[ 합성예Synthetic example 61] Mat 61의 합성 61] Synthesis of Mat 61

Figure pat00083
Figure pat00083

반응물로 4-([1,1'-바이페닐]-4-일)-6-(5-브로모-4'-(피리딘-3-일)-[1,1'-바이페닐]-3-일)-2-페닐피리미딘을 사용한 것을 제외하고는 [합성예 8]과 동일한 과정을 수행하여 목적 화합물 5.7g을 얻었다; HRMS [M]+: 737.91The reaction was carried out using 4 - ([1,1'-biphenyl] -4-yl) -6- (5-bromo-4 ' - yl) -2-phenylpyrimidine was used in place of 2-chloro-4-fluorobenzaldehyde, the procedure of Synthetic Example 8 was repeated to give the desired compound (5.7 g; HRMS [M] < + >: 737.91

[[ 합성예Synthetic example 62] Mat 62의 합성 62] Synthesis of Mat 62

Figure pat00084
Figure pat00084

반응물로 4-([1,1'-바이페닐]-4-일)-6-(5-브로모-4'-(피리딘-3-일)-[1,1'-바이페닐]-3-일)-2-페닐피리미딘을 사용한 것을 제외하고는 [합성예 9]과 동일한 과정을 수행하여 목적 화합물 4.6g을 얻었다; HRMS [M]+: 729.93The reaction was carried out using 4 - ([1,1'-biphenyl] -4-yl) -6- (5-bromo-4 ' -Yl) -2-phenylpyrimidine was used in place of 2-chloro-4-fluorobenzyl chloride, the procedure of Synthetic Example 9 was repeated to give the desired compound (4.6 g; HRMS [M] < + >: 729.93

[[ 합성예Synthetic example 63] Mat 63의 합성 63] Synthesis of Mat 63

Figure pat00085
Figure pat00085

반응물로 4-([1,1'-바이페닐]-4-일)-6-(5-브로모-4'-(피리딘-3-일)-[1,1'-바이페닐]-3-일)-2-페닐피리미딘을 사용한 것을 제외하고는 [합성예 10]과 동일한 과정을 수행하여 목적 화합물 4.7g을 얻었다; HRMS [M]+: 778.96The reaction was carried out using 4 - ([1,1'-biphenyl] -4-yl) -6- (5-bromo-4 ' -Yl) -2-phenylpyrimidine was used in place of 2-chloro-4-methylpyridine, the procedure of Synthetic Example 10 was repeated to give the desired compound (4.7 g); HRMS [M] < + >: 778.96

[[ 합성예Synthetic example 64] Mat 64의 합성 64] Synthesis of Mat 64

Figure pat00086
Figure pat00086

반응물로 4-([1,1'-바이페닐]-4-일)-6-(5-브로모-4'-(피리딘-3-일)-[1,1'-바이페닐]-3-일)-2-페닐피리미딘 을 사용한 것을 제외하고는 [합성예 11]과 동일한 과정을 수행하여 목적 화합물 5.1g을 얻었다; HRMS [M]+: 703.85The reaction was carried out using 4 - ([1,1'-biphenyl] -4-yl) -6- (5-bromo-4 ' -Yl) -2-phenylpyrimidine was used in place of 2-chloro-4-fluorobenzyl chloride in the same manner as in [Synthesis Example 11], 5.1 g of the desired compound was obtained; HRMS [M] < + >: 703.85

[[ 합성예Synthetic example 65] Mat 65의 합성 65] Synthesis of Mat 65

Figure pat00087
Figure pat00087

반응물로 4-([1,1'-바이페닐]-4-일)-6-(5-브로모-4'-(피리딘-3-일)-[1,1'-바이페닐]-3-일)-2-페닐피리미딘을 사용한 것을 제외하고는 [합성예 12]과 동일한 과정을 수행하여 목적 화합물 4.2g을 얻었다; HRMS [M]+: 702.86The reaction was carried out using 4 - ([1,1'-biphenyl] -4-yl) -6- (5-bromo-4 ' - yl) -2-phenylpyrimidine was used in place of 2-chloro-4-fluorobenzaldehyde to obtain the desired compound (4.2 g); HRMS [M] < + >: 702.86

[[ 합성예Synthetic example 66] Mat 66의 합성 66] Synthesis of Mat 66

Figure pat00088
Figure pat00088

반응물로 4-([1,1'-바이페닐]-4-일)-6-(5-브로모-4'-(피리딘-3-일)-[1,1'-바이페닐]-3-일)-2-페닐피리미딘을 사용한 것을 제외하고는 [합성예 13]과 동일한 과정을 수행하여 목적 화합물 4.7g을 얻었다; HRMS [M]+: 778.96The reaction was carried out using 4 - ([1,1'-biphenyl] -4-yl) -6- (5-bromo-4 ' -Yl) -2-phenylpyrimidine was used in place of 2-chloro-4-fluorobenzaldehyde, the procedure of Synthetic Example 13 was repeated to give the desired compound (4.7 g); HRMS [M] < + >: 778.96

[[ 합성예Synthetic example 67] Mat 67의 합성 67] Synthesis of Mat 67

Figure pat00089
Figure pat00089

반응물로 4-([1,1'-바이페닐]-4-일)-6-(5-브로모-4'-(피리딘-3-일)-[1,1'-바이페닐]-3-일)-2-페닐피리미딘을 사용한 것을 제외하고는 [합성예 14]과 동일한 과정을 수행하여 목적 화합물 3.8g을 얻었다; HRMS [M]+: 719.84The reaction was carried out using 4 - ([1,1'-biphenyl] -4-yl) -6- (5-bromo-4 ' -Yl) -2-phenylpyrimidine was used in place of 2-chloro-4-fluorobenzaldehyde, the procedure of Synthetic Example 14 was repeated to give the desired compound (3.8 g; HRMS [M] < + >: 719.84

[[ 합성예Synthetic example 68] Mat 68의 합성 68] Synthesis of Mat 68

Figure pat00090
Figure pat00090

반응물로 4-([1,1'-바이페닐]-4-일)-6-(5-브로모-4'-(피리딘-3-일)-[1,1'-바이페닐]-3-일)-2-페닐피리미딘을 사용한 것을 제외하고는 [합성예 15]과 동일한 과정을 수행하여 목적 화합물 4.5 g을 얻었다; HRMS [M]+: 718.86The reaction was carried out using 4 - ([1,1'-biphenyl] -4-yl) -6- (5-bromo-4 ' - yl) -2-phenylpyrimidine was used in place of 2-chloro-4-fluorobenzaldehyde to obtain the title compound (4.5 g); HRMS [M] < + >: 718.86

[[ 합성예Synthetic example 69] Mat 69의 합성 69] Synthesis of Mat 69

Figure pat00091
Figure pat00091

반응물로 4-([1,1'-바이페닐]-4-일)-6-(5-브로모-4'-(피리딘-3-일)-[1,1'-바이페닐]-3-일)-2-페닐피리미딘을 사용한 것을 제외하고는 [합성예 16]과 동일한 과정을 수행하여 목적 화합물 5.5g을 얻었다; HRMS [M]+: 715.86The reaction was carried out using 4 - ([1,1'-biphenyl] -4-yl) -6- (5-bromo-4 ' -Yl) -2-phenylpyrimidine was used in place of 2-bromo-4-methylpyridine, 5.5 g of the title compound was obtained by carrying out the same processes as in [Synthesis Example 16]; HRMS [M] < + >: 715.86

[[ 합성예Synthetic example 70] Mat 70의 합성 70] Synthesis of Mat 70

Figure pat00092
Figure pat00092

반응물로 4-([1,1'-바이페닐]-4-일)-6-(5-브로모-4'-(피리딘-3-일)-[1,1'-바이페닐]-3-일)-2-페닐피리미딘을 사용한 것을 제외하고는 [합성예 17]과 동일한 과정을 수행하여 목적 화합물 4.9g을 얻었다; HRMS [M]+: 664.81The reaction was carried out using 4 - ([1,1'-biphenyl] -4-yl) -6- (5-bromo-4 ' -Yl) -2-phenylpyrimidine was used in place of 2-chloro-4-fluorobenzaldehyde, the procedure of Synthetic Example 17 was repeated to give the desired compound (4.9 g; HRMS [M] < + >: 664.81

[[ 합성예Synthetic example 71] Mat 71의 합성 71] Synthesis of Mat 71

Figure pat00093
Figure pat00093

반응물로 2-(3-(6-([1,1'-바이페닐]-4-일)-2-페닐피리미딘-4-일)-5-브로모페닐)-1,10-페난트롤린을 사용한 것을 제외하고는 [합성예 1]과 동일한 과정을 수행하여 목적 화합물 6.4g을 얻었다; HRMS [M]+: 637.77The reaction was carried out using 2- (3- (6 - ([1,1'-biphenyl] -4-yl) -2-phenylpyrimidin-4-yl) -5-bromophenyl) -1,10- The same procedure as in [Synthesis Example 1] was carried out except for using phosphorus to obtain 6.4 g of the desired compound; HRMS [M] < + >: 637.77

[[ 합성예Synthetic example 72] Mat 72의 합성 72] Synthesis of Mat 72

Figure pat00094
Figure pat00094

반응물로 2-(3-(6-([1,1'-바이페닐]-4-일)-2-페닐피리미딘-4-일)-5-브로모페닐)-1,10-페난트롤린을 사용한 것을 제외하고는 [합성예 2]과 동일한 과정을 수행하여 목적 화합물 5.9g을 얻었다; HRMS [M]+: 688.26The reaction was carried out using 2- (3- (6 - ([1,1'-biphenyl] -4-yl) -2-phenylpyrimidin-4-yl) -5-bromophenyl) -1,10- The same procedure as in [Synthesis Example 2] was carried out except for using phosphorus to obtain 5.9 g of the desired compound; HRMS [M] < + >: 688.26

[[ 합성예Synthetic example 73] Mat 73의 합성 73] Synthesis of Mat 73

Figure pat00095
Figure pat00095

반응물로 2-(3-(6-([1,1'-바이페닐]-4-일)-2-페닐피리미딘-4-일)-5-브로모페닐)-1,10-페난트롤린을 사용한 것을 제외하고는 [합성예 3]과 동일한 과정을 수행하여 목적 화합물 5.2g을 얻었다; HRMS [M]+: 688.83The reaction was carried out using 2- (3- (6 - ([1,1'-biphenyl] -4-yl) -2-phenylpyrimidin-4-yl) -5-bromophenyl) -1,10- The same procedure as in [Synthesis Example 3] was carried out except that phosphorus was used to obtain 5.2 g of the target compound; HRMS [M] < + >: 688.83

[[ 합성예Synthetic example 74] Mat 74의 합성 74] Synthesis of Mat 74

Figure pat00096
Figure pat00096

반응물로 2-(3-(6-([1,1'-바이페닐]-4-일)-2-페닐피리미딘-4-일)-5-브로모페닐)-1,10-페난트롤린을 사용한 것을 제외하고는 [합성예 4]과 동일한 과정을 수행하여 목적 화합물 6.8g을 얻었다; HRMS [M]+: 738.89The reaction was carried out using 2- (3- (6 - ([1,1'-biphenyl] -4-yl) -2-phenylpyrimidin-4-yl) -5-bromophenyl) -1,10- The same procedure as in [Synthesis Example 4] was carried out except that phosphorus was used to obtain 6.8 g of the desired compound; HRMS [M] < + >: 738.89

[[ 합성예Synthetic example 75] Mat 75의 합성 75] Synthesis of Mat 75

Figure pat00097
Figure pat00097

반응물로 2-(3-(6-([1,1'-바이페닐]-4-일)-2-페닐피리미딘-4-일)-5-브로모페닐)-1,10-페난트롤린을 사용한 것을 제외하고는 [합성예 5]과 동일한 과정을 수행하여 목적 화합물 7.6g을 얻었다; HRMS [M]+: 738.89The reaction was carried out using 2- (3- (6 - ([1,1'-biphenyl] -4-yl) -2-phenylpyrimidin-4-yl) -5-bromophenyl) -1,10- The same procedure as in [Synthesis Example 5] was carried out except for using phosphorus to obtain 7.6 g of the desired compound; HRMS [M] < + >: 738.89

[[ 합성예Synthetic example 76] Mat 76의 합성 76] Synthesis of Mat 76

Figure pat00098
Figure pat00098

반응물로 2-(3-(6-([1,1'-바이페닐]-4-일)-2-페닐피리미딘-4-일)-5-브로모페닐)-1,10-페난트롤린을 사용한 것을 제외하고는 [합성예 6]과 동일한 과정을 수행하여 목적 화합물 7.9g을 얻었다; HRMS [M]+: 814.99The reaction was carried out using 2- (3- (6 - ([1,1'-biphenyl] -4-yl) -2-phenylpyrimidin-4-yl) -5-bromophenyl) -1,10- The same procedure as in [Synthesis Example 6] was conducted except that phosphorus was used to obtain 7.9 g of the desired compound; HRMS [M] < + >: 814.99

[[ 합성예Synthetic example 77] Mat 77의 합성 77] Synthesis of Mat 77

Figure pat00099
Figure pat00099

반응물로 2-(3-(6-([1,1'-바이페닐]-4-일)-2-페닐피리미딘-4-일)-5-브로모페닐)-1,10-페난트롤린을 사용한 것을 제외하고는 [합성예 7]과 동일한 과정을 수행하여 목적 화합물 8.3g을 얻었다; HRMS [M]+: 788.95The reaction was carried out using 2- (3- (6 - ([1,1'-biphenyl] -4-yl) -2-phenylpyrimidin-4-yl) -5-bromophenyl) -1,10- The same procedure as in [Synthesis Example 7] was conducted except that phosphorus was used to obtain 8.3 g of the target compound; HRMS [M] < + >: 788.95

[[ 합성예Synthetic example 78] Mat 78의 합성 78] Synthesis of Mat 78

Figure pat00100
Figure pat00100

반응물로 2-(3-(6-([1,1'-바이페닐]-4-일)-2-페닐피리미딘-4-일)-5-브로모페닐)-1,10-페난트롤린을 사용한 것을 제외하고는 [합성예 8]과 동일한 과정을 수행하여 목적 화합물 4.3g을 얻었다; HRMS [M]+: 762.92The reaction was carried out using 2- (3- (6 - ([1,1'-biphenyl] -4-yl) -2-phenylpyrimidin-4-yl) -5-bromophenyl) -1,10- The same procedure as in [Synthesis Example 8] was conducted except that phosphorus was used to obtain 4.3 g of the target compound; HRMS [M] < + >: 762.92

[[ 합성예Synthetic example 79] Mat 79의 합성 79] Synthesis of Mat 79

Figure pat00101
Figure pat00101

반응물로 2-(3-(6-([1,1'-바이페닐]-4-일)-2-페닐피리미딘-4-일)-5-브로모페닐)-1,10-페난트롤린을 사용한 것을 제외하고는 [합성예 9]과 동일한 과정을 수행하여 목적 화합물 3.6g을 얻었다; HRMS [M]+: 754.94The reaction was carried out using 2- (3- (6 - ([1,1'-biphenyl] -4-yl) -2-phenylpyrimidin-4-yl) -5-bromophenyl) -1,10- The same procedure as in [Synthesis Example 9] was conducted except that phosphorus was used to obtain 3.6 g of the target compound; HRMS [M] < + >: 754.94

[[ 합성예Synthetic example 80] Mat 80의 합성 80] Synthesis of Mat 80

Figure pat00102
Figure pat00102

반응물로 2-(3-(6-([1,1'-바이페닐]-4-일)-2-페닐피리미딘-4-일)-5-브로모페닐)-1,10-페난트롤린을 사용한 것을 제외하고는 [합성예 10]과 동일한 과정을 수행하여 목적 화합물 4.1g을 얻었다; HRMS [M]+: 803.97The reaction was carried out using 2- (3- (6 - ([1,1'-biphenyl] -4-yl) -2-phenylpyrimidin-4-yl) -5-bromophenyl) -1,10- The procedure of Synthesis Example 10 was followed except that phosphorus was used to obtain 4.1 g of the desired compound; HRMS [M] < + >: 803.97

[[ 합성예Synthetic example 81] Mat 81의 합성 81] Synthesis of Mat 81

Figure pat00103
Figure pat00103

반응물로 2-(3-(6-([1,1'-바이페닐]-4-일)-2-페닐피리미딘-4-일)-5-브로모페닐)-1,10-페난트롤린을 사용한 것을 제외하고는 [합성예 11]과 동일한 과정을 수행하여 목적 화합물 3.5g을 얻었다; HRMS [M]+: 728.26The reaction was carried out using 2- (3- (6 - ([1,1'-biphenyl] -4-yl) -2-phenylpyrimidin-4-yl) -5-bromophenyl) -1,10- The same procedure as in [Synthesis Example 11] was conducted except that phosphorus was used to obtain 3.5 g of the desired compound; HRMS [M] < + >: 728.26

[[ 합성예Synthetic example 82] Mat 82의 합성 82] Synthesis of Mat 82

Figure pat00104
Figure pat00104

반응물로 2-(3-(6-([1,1'-바이페닐]-4-일)-2-페닐피리미딘-4-일)-5-브로모페닐)-1,10-페난트롤린을 사용한 것을 제외하고는 [합성예 12]과 동일한 과정을 수행하여 목적 화합물 2.9g을 얻었다; HRMS [M]+: 727.87The reaction was carried out using 2- (3- (6 - ([1,1'-biphenyl] -4-yl) -2-phenylpyrimidin-4-yl) -5-bromophenyl) -1,10- The same procedure as in [Synthesis Example 12] was carried out except that phosphorus was used to obtain 2.9 g of the desired compound; HRMS [M] < + >: 727.87

[[ 합성예Synthetic example 83] Mat 83의 합성 83] Synthesis of Mat 83

Figure pat00105
Figure pat00105

반응물로 2-(3-(6-([1,1'-바이페닐]-4-일)-2-페닐피리미딘-4-일)-5-브로모페닐)-1,10-페난트롤린을 사용한 것을 제외하고는 [합성예 13]과 동일한 과정을 수행하여 목적 화합물 3.1g을 얻었다; HRMS [M]+: 803.97The reaction was carried out using 2- (3- (6 - ([1,1'-biphenyl] -4-yl) -2-phenylpyrimidin-4-yl) -5-bromophenyl) -1,10- The same procedure as in [Synthesis Example 13] was conducted except that phosphorus was used to obtain 3.1 g of the target compound; HRMS [M] < + >: 803.97

[[ 합성예Synthetic example 84] Mat 84의 합성 84] Synthesis of Mat 84

Figure pat00106
Figure pat00106

반응물로 2-(3-(6-([1,1'-바이페닐]-4-일)-2-페닐피리미딘-4-일)-5-브로모페닐)-1,10-페난트롤린을 사용한 것을 제외하고는 [합성예 14]과 동일한 과정을 수행하여 목적 화합물 3.3g을 얻었다; HRMS [M]+: 744.85The reaction was carried out using 2- (3- (6 - ([1,1'-biphenyl] -4-yl) -2-phenylpyrimidin-4-yl) -5-bromophenyl) -1,10- The same procedure as in [Synthesis Example 14] was conducted except that phosphorus was used to obtain 3.3 g of the desired compound; HRMS [M] < + >: 744.85

[[ 합성예Synthetic example 85] Mat 85의 합성 85] Synthesis of Mat 85

Figure pat00107
Figure pat00107

반응물로 2-(3-(6-([1,1'-바이페닐]-4-일)-2-페닐피리미딘-4-일)-5-브로모페닐)-1,10-페난트롤린을 사용한 것을 제외하고는 [합성예 15]과 동일한 과정을 수행하여 목적 화합물 2.4g을 얻었다; HRMS [M]+: 743.87The reaction was carried out using 2- (3- (6 - ([1,1'-biphenyl] -4-yl) -2-phenylpyrimidin-4-yl) -5-bromophenyl) -1,10- The same procedure as in [Synthesis Example 15] was conducted except that phosphorus was used to obtain 2.4 g of the target compound; HRMS [M] < + >: 743.87

[[ 합성예Synthetic example 86] Mat 86의 합성 86] Synthesis of Mat 86

Figure pat00108
Figure pat00108

반응물로 2-(3-(6-([1,1'-바이페닐]-4-일)-2-페닐피리미딘-4-일)-5-브로모페닐)-1,10-페난트롤린을 사용한 것을 제외하고는 [합성예 17]과 동일한 과정을 수행하여 목적 화합물 4.6g을 얻었다; HRMS [M]+: 689.82The reaction was carried out using 2- (3- (6 - ([1,1'-biphenyl] -4-yl) -2-phenylpyrimidin-4-yl) -5-bromophenyl) -1,10- The same procedure as in [Synthesis Example 17] was carried out except for using phosphorus to obtain 4.6 g of the desired compound; HRMS [M] < + >: 689.82

[[ 합성예Synthetic example 87] Mat 87의 합성 87] Synthesis of Mat 87

Figure pat00109
Figure pat00109

반응물로 2-(3-(6-([1,1'-바이페닐]-4-일)-2-페닐피리미딘-4-일)-5-브로모페닐)-1,10-페난트롤린을 사용한 것을 제외하고는 [합성예 18]과 동일한 과정을 수행하여 목적 화합물 3.9g을 얻었다; HRMS [M]+: 715.86The reaction was carried out using 2- (3- (6 - ([1,1'-biphenyl] -4-yl) -2-phenylpyrimidin-4-yl) -5-bromophenyl) -1,10- The same procedure as in [Synthesis Example 18] was conducted except that phosphorus was used to obtain 3.9 g of the desired compound; HRMS [M] < + >: 715.86

[[ 합성예Synthetic example 88] Mat 88의 합성 88] Synthesis of Mat 88

Figure pat00110
Figure pat00110

반응물로 2-([1,1'-바이페닐]-4-일)-4-(3-브로모-5-(피리딘-3-일)페닐)-6-페닐-1,3,5-트리아진을 사용한 것을 제외하고는 [합성예 1]과 동일한 과정을 수행하여 목적 화합물 4.1g을 얻었다; HRMS [M]+: 538.654- (3-bromo-5- (pyridin-3-yl) phenyl) -6-phenyl-1,3,5- The same procedure as in [Synthesis Example 1] was carried out except that triazine was used to obtain 4.1 g of the desired compound; HRMS [M] < + >: 538.65

[[ 합성예Synthetic example 89] Mat 89의 합성 89] Synthesis of Mat 89

Figure pat00111
Figure pat00111

반응물로 2-([1,1'-바이페닐]-4-일)-4-(3-브로모-5-(피리딘-3-일)페닐)-6-페닐-1,3,5-트리아진을 사용한 것을 제외하고는 [합성예 4]과 동일한 과정을 수행하여 목적 화합물 3.8g을 얻었다; HRMS [M]+: 638.784- (3-bromo-5- (pyridin-3-yl) phenyl) -6-phenyl-1,3,5- The same procedure as in [Synthesis Example 4] was conducted except that triazine was used to obtain 3.8 g of the target compound; HRMS [M] < + >: 638.78

[[ 합성예Synthetic example 90] Mat 90의 합성 90] Synthesis of Mat 90

Figure pat00112
Figure pat00112

반응물로 2-([1,1'-바이페닐]-4-일)-4-(3-브로모-5-(피리딘-3-일)페닐)-6-페닐-1,3,5-트리아진을 사용한 것을 제외하고는 [합성예 5]과 동일한 과정을 수행하여 목적 화합물 2.9g을 얻었다; HRMS [M]+: 638.774- (3-bromo-5- (pyridin-3-yl) phenyl) -6-phenyl-1,3,5- The same procedure as in [Synthesis Example 5] was carried out except that triazine was used to obtain 2.9 g of the title compound; HRMS [M] < + >: 638.77

[[ 합성예Synthetic example 91] Mat 91의 합성 91] Synthesis of Mat 91

Figure pat00113
Figure pat00113

반응물로 2-([1,1'-바이페닐]-4-일)-4-(3-브로모-5-(피리딘-3-일)페닐)-6-페닐-1,3,5-트리아진을 사용한 것을 제외하고는 [합성예 7]과 동일한 과정을 수행하여 목적 화합물 4.0g을 얻었다; HRMS [M]+: 688.834- (3-bromo-5- (pyridin-3-yl) phenyl) -6-phenyl-1,3,5- The same procedure as in [Synthesis Example 7] was conducted except that triazine was used to obtain 4.0 g of the desired compound; HRMS [M] < + >: 688.83

[[ 합성예Synthetic example 92] Mat 92의 합성 92] Synthesis of Mat 92

Figure pat00114
Figure pat00114

반응물로 2-([1,1'-바이페닐]-4-일)-4-(3-브로모-5-(피리딘-3-일)페닐)-6-페닐-1,3,5-트리아진을 사용한 것을 제외하고는 [합성예 9]과 동일한 과정을 수행하여 목적 화합물 3.1g을 얻었다; HRMS [M]+: 654.824- (3-bromo-5- (pyridin-3-yl) phenyl) -6-phenyl-1,3,5- The same procedure as in [Synthesis Example 9] was conducted except that triazine was used to obtain 3.1 g of the target compound; HRMS [M] < + >: 654.82

[[ 합성예Synthetic example 93] Mat 93의 합성 93] Synthesis of Mat 93

Figure pat00115
Figure pat00115

반응물로 2-([1,1'-바이페닐]-4-일)-4-(3-브로모-5-(피리딘-3-일)페닐)-6-페닐-1,3,5-트리아진을 사용한 것을 제외하고는 [합성예 10]과 동일한 과정을 수행하여 목적 화합물 4.4g을 얻었다; HRMS [M]+: 703.854- (3-bromo-5- (pyridin-3-yl) phenyl) -6-phenyl-1,3,5- The same procedure as in [Synthesis Example 10] was conducted except that triazine was used to obtain 4.4 g of the desired compound; HRMS [M] < + >: 703.85

[[ 합성예Synthetic example 94] Mat 94의 합성 94] Synthesis of Mat 94

Figure pat00116
Figure pat00116

반응물로 2-([1,1'-바이페닐]-4-일)-4-(3-브로모-5-(피리딘-3-일)페닐)-6-페닐-1,3,5-트리아진을 사용한 것을 제외하고는 [합성예 12]과 동일한 과정을 수행하여 목적 화합물 2.5g을 얻었다; HRMS [M]+: 627.754- (3-bromo-5- (pyridin-3-yl) phenyl) -6-phenyl-1,3,5- The same procedure as in [Synthesis Example 12] was conducted except that triazine was used to obtain 2.5 g of the desired compound; HRMS [M] < + >: 627.75

[[ 합성예Synthetic example 95] Mat 95의 합성 95] Synthesis of Mat 95

Figure pat00117
Figure pat00117

반응물로 2-([1,1'-바이페닐]-4-일)-4-(3-브로모-5-(피리딘-3-일)페닐)-6-페닐-1,3,5-트리아진을 사용한 것을 제외하고는 [합성예 15]과 동일한 과정을 수행하여 목적 화합물 2.1g을 얻었다; HRMS [M]+: 643.754- (3-bromo-5- (pyridin-3-yl) phenyl) -6-phenyl-1,3,5- The same procedure as in [Synthesis Example 15] was conducted except that triazine was used to obtain 2.1 g of the desired compound; HRMS [M] < + >: 643.75

[[ 합성예Synthetic example 96] Mat 96의 합성 96] Synthesis of Mat 96

Figure pat00118
Figure pat00118

반응물로 2-([1,1'-바이페닐]-4-일)-4-(3-브로모-5-(피리딘-3-일)페닐)-6-페닐-1,3,5-트리아진을 사용한 것을 제외하고는 [합성예 16]과 동일한 과정을 수행하여 목적 화합물 2.6g을 얻었다; HRMS [M]+: 640.754- (3-bromo-5- (pyridin-3-yl) phenyl) -6-phenyl-1,3,5- The same procedure as in [Synthesis Example 16] was conducted except that triazine was used to obtain 2.6 g of the target compound; HRMS [M] < + >: 640.75

[[ 합성예Synthetic example 97] Mat 97의 합성 97] Synthesis of Mat 97

Figure pat00119
Figure pat00119

반응물로 2-([1,1'-바이페닐]-4-일)-4-(3-브로모-5-(피리딘-3-일)페닐)-6-페닐-1,3,5-트리아진을 사용한 것을 제외하고는 [합성예 17]과 동일한 과정을 수행하여 목적 화합물 2.9g을 얻었다; HRMS [M]+: 589.704- (3-bromo-5- (pyridin-3-yl) phenyl) -6-phenyl-1,3,5- The same procedure as in [Synthesis Example 17] was conducted except that triazine was used to obtain 2.9 g of the title compound; HRMS [M] < + >: 589.70

[[ 합성예Synthetic example 98] Mat 98의 합성 98] Synthesis of Mat 98

Figure pat00120
Figure pat00120

반응물로 4-([1,1'-바이페닐]-4-일)-6-(3-브로모-5-(피리딘-3-일)페닐)-2-페닐피리미딘을 사용한 것을 제외하고는 [합성예 18]과 동일한 과정을 수행하여 목적 화합물 3.8g을 얻었다; HRMS [M]+: 614.72Except that 4 - ([1,1'-biphenyl] -4-yl) -6- (3-bromo-5- (pyridin-3- yl) phenyl) -2-phenylpyrimidine was used as a reactant Was subjected to the same procedure as in [Synthesis Example 18] to obtain 3.8 g of the desired compound; HRMS [M] < + >: 614.72

[[ 합성예Synthetic example 99] Mat 99의 합성 99] Synthesis of Mat 99

Figure pat00121
Figure pat00121

반응물로 2-([1,1'-바이페닐]-4-일)-4-(3-브로모-5-(피리딘-4-일)페닐)-6-페닐-1,3,5-트리아진을 사용한 것을 제외하고는 [합성예 22]과 동일한 과정을 수행하여 목적 화합물 3.6g을 얻었다; HRMS [M]+: 638.774- (3-bromo-5- (pyridin-4-yl) phenyl) -6-phenyl-1,3,5- The same procedure as in [Synthesis Example 22] was conducted except that triazine was used to obtain 3.6 g of the desired compound; HRMS [M] < + >: 638.77

[[ 합성예Synthetic example 100] Mat 100의 합성 100] Synthesis of Mat 100

Figure pat00122
Figure pat00122

반응물로 2-([1,1'-바이페닐]-4-일)-4-(3-브로모-5-(피리딘-4-일)페닐)-6-페닐-1,3,5-트리아진을 사용한 것을 제외하고는 [합성예 23]과 동일한 과정을 수행하여 목적 화합물 3.0g을 얻었다; HRMS [M]+: 638.774- (3-bromo-5- (pyridin-4-yl) phenyl) -6-phenyl-1,3,5- The same procedure as in [Synthesis Example 23] was conducted except that triazine was used to obtain 3.0 g of the objective compound; HRMS [M] < + >: 638.77

[[ 합성예Synthetic example 101] Mat 101의 합성 101] Synthesis of Mat 101

Figure pat00123
Figure pat00123

반응물로 2-([1,1'-바이페닐]-4-일)-4-(3-브로모-5-(피리딘-4-일)페닐)-6-페닐-1,3,5-트리아진을 사용한 것을 제외하고는 [합성예 25]과 동일한 과정을 수행하여 목적 화합물 3.2g을 얻었다; HRMS [M]+: 688.834- (3-bromo-5- (pyridin-4-yl) phenyl) -6-phenyl-1,3,5- The same procedure as in [Synthesis Example 25] was conducted except that triazine was used to obtain 3.2 g of the desired compound; HRMS [M] < + >: 688.83

[[ 합성예Synthetic example 102] Mat 102의 합성 102] Synthesis of Mat 102

Figure pat00124
Figure pat00124

반응물로 2-([1,1'-바이페닐]-4-일)-4-(3-브로모-5-(피리딘-4-일)페닐)-6-페닐-1,3,5-트리아진을 사용한 것을 제외하고는 [합성예 27]과 동일한 과정을 수행하여 목적 화합물 2.9g을 얻었다; HRMS [M]+: 654.824- (3-bromo-5- (pyridin-4-yl) phenyl) -6-phenyl-1,3,5- The same procedure as in [Synthesis Example 27] was conducted except that triazine was used to obtain 2.9 g of the title compound; HRMS [M] < + >: 654.82

[[ 합성예Synthetic example 103] Mat 103의 합성 103] Synthesis of Mat 103

Figure pat00125
Figure pat00125

반응물로 2-([1,1'-바이페닐]-4-일)-4-(3-브로모-5-(피리딘-4-일)페닐)-6-페닐-1,3,5-트리아진을 사용한 것을 제외하고는 [합성예 30]과 동일한 과정을 수행하여 목적 화합물 2.1g을 얻었다; HRMS [M]+: 627.754- (3-bromo-5- (pyridin-4-yl) phenyl) -6-phenyl-1,3,5- The same procedure as in [Synthesis Example 30] was conducted except that triazine was used to obtain 2.1 g of the desired compound; HRMS [M] < + >: 627.75

[[ 합성예Synthetic example 104] Mat 104의 합성 104] Synthesis of Mat 104

Figure pat00126
Figure pat00126

반응물로 2-([1,1'-바이페닐]-4-일)-4-(3-브로모-5-(피리딘-4-일)페닐)-6-페닐-1,3,5-트리아진을 사용한 것을 제외하고는 [합성예 34]과 동일한 과정을 수행하여 목적 화합물 2.8g을 얻었다; HRMS [M]+: 640.754- (3-bromo-5- (pyridin-4-yl) phenyl) -6-phenyl-1,3,5- The same procedure as in [Synthesis Example 34] was conducted except that triazine was used to obtain 2.8 g of the desired compound; HRMS [M] < + >: 640.75

[[ 합성예Synthetic example 105] Mat 105의 합성 105] Synthesis of Mat 105

Figure pat00127
Figure pat00127

반응물로 2-([1,1'-바이페닐]-4-일)-4-(3-브로모-5-(피리딘-4-일)페닐)-6-페닐-1,3,5-트리아진을 사용한 것을 제외하고는 [합성예 35]과 동일한 과정을 수행하여 목적 화합물 2.3g을 얻었다; HRMS [M]+: 589.704- (3-bromo-5- (pyridin-4-yl) phenyl) -6-phenyl-1,3,5- The same procedure as in [Synthesis Example 35] was conducted except that triazine was used to obtain 2.3 g of the target compound; HRMS [M] < + >: 589.70

[[ 합성예Synthetic example 106] Mat 106의 합성 106] Synthesis of Mat 106

Figure pat00128
Figure pat00128

반응물로 2-([1,1'-바이페닐]-4-일)-4-(3-브로모-5-(피리딘-4-일)페닐)-6-페닐-1,3,5-트리아진을 사용한 것을 제외하고는 [합성예 36]과 동일한 과정을 수행하여 목적 화합물 2.8g을 얻었다; HRMS [M]+: 615.744- (3-bromo-5- (pyridin-4-yl) phenyl) -6-phenyl-1,3,5- The same procedure as in [Synthesis Example 36] was conducted except that triazine was used to obtain 2.8 g of the desired compound; HRMS [M] < + >: 615.74

[[ 합성예Synthetic example 107] Mat 107의 합성 107] Synthesis of Mat 107

Figure pat00129
Figure pat00129

반응물로 8-(3-(4-([1,1'-바이페닐]-4-일)-6-페닐-1,3,5-트리아진-2-일)-5-브로모페닐)퀴놀린을 사용한 것을 제외하고는 [합성예 1]과 동일한 과정을 수행하여 목적 화합물 2.0g을 얻었다; HRMS [M]+: 588.71As a reaction product, 8- (3- (4 - ([1,1'-biphenyl] -4-yl) -6- Quinoline, the same procedure as in [Synthesis Example 1] was conducted to obtain 2.0 g of the target compound; HRMS [M] < + >: 588.71

[[ 합성예Synthetic example 108] Mat 108의 합성 108] Synthesis of Mat 108

Figure pat00130
Figure pat00130

반응물로 8-(3-(4-([1,1'-바이페닐]-4-일)-6-페닐-1,3,5-트리아진-2-일)-5-브로모페닐)퀴놀린을 사용한 것을 제외하고는 [합성예 3]과 동일한 과정을 수행하여 목적 화합물 2.9g을 얻었다; HRMS [M]+: 638.77As a reaction product, 8- (3- (4 - ([1,1'-biphenyl] -4-yl) -6- Quinoline, the procedure of Synthesis Example 3 was repeated to obtain 2.9 g of the desired compound; HRMS [M] < + >: 638.77

[[ 합성예Synthetic example 109] Mat 109의 합성 109] Synthesis of Mat 109

Figure pat00131
Figure pat00131

반응물로 8-(3-(4-([1,1'-바이페닐]-4-일)-6-페닐-1,3,5-트리아진-2-일)-5-브로모페닐)퀴놀린을 사용한 것을 제외하고는 [합성예 4]과 동일한 과정을 수행하여 목적 화합물 3.3g을 얻었다; HRMS [M]+: 688.83As a reaction product, 8- (3- (4 - ([1,1'-biphenyl] -4-yl) -6- Quinoline, the same procedure as in [Synthesis Example 4] was conducted to obtain 3.3 g of the objective compound; HRMS [M] < + >: 688.83

[[ 합성예Synthetic example 110] Mat 110의 합성 110] Synthesis of Mat 110

Figure pat00132
Figure pat00132

반응물로 8-(3-(4-([1,1'-바이페닐]-4-일)-6-페닐-1,3,5-트리아진-2-일)-5-브로모페닐)퀴놀린을 사용한 것을 제외하고는 [합성예 7]과 동일한 과정을 수행하여 목적 화합물 3.7g을 얻었다; HRMS [M]+: 738.89As a reaction product, 8- (3- (4 - ([1,1'-biphenyl] -4-yl) -6- Quinoline, the procedure of Synthesis Example 7 was repeated to obtain the desired compound (3.7 g); HRMS [M] < + >: 738.89

[[ 합성예Synthetic example 111] Mat 111의 합성 111] Synthesis of Mat 111

Figure pat00133
Figure pat00133

반응물로 8-(3-(4-([1,1'-바이페닐]-4-일)-6-페닐-1,3,5-트리아진-2-일)-5-브로모페닐)퀴놀린을 사용한 것을 제외하고는 [합성예 9]과 동일한 과정을 수행하여 목적 화합물 2.6g을 얻었다; HRMS [M]+: 704.88As a reaction product, 8- (3- (4 - ([1,1'-biphenyl] -4-yl) -6- Quinoline, the procedure of Synthesis Example 9 was carried out to obtain 2.6 g of the target compound; HRMS [M] < + >: 704.88

[[ 합성예Synthetic example 112] Mat 112의 합성 112] Synthesis of Mat 112

Figure pat00134
Figure pat00134

반응물로 8-(3-(4-([1,1'-바이페닐]-4-일)-6-페닐-1,3,5-트리아진-2-일)-5-브로모페닐)퀴놀린을 사용한 것을 제외하고는 [합성예 12]과 동일한 과정을 수행하여 목적 화합물 2.0g을 얻었다; HRMS [M]+: 677.81As a reaction product, 8- (3- (4 - ([1,1'-biphenyl] -4-yl) -6- Quinoline, the procedure of Synthesis Example 12 was carried out to obtain 2.0 g of the target compound; HRMS [M] < + >: 677.81

[[ 합성예Synthetic example 113] Mat 113의 합성 113] Synthesis of Mat 113

Figure pat00135
Figure pat00135

반응물로 8-(3-(4-([1,1'-바이페닐]-4-일)-6-페닐-1,3,5-트리아진-2-일)-5-브로모페닐)퀴놀린을 사용한 것을 제외하고는 [합성예 12]과 동일한 과정을 수행하여 목적 화합물 3.4g을 얻었다; HRMS [M]+: 677.81As a reaction product, 8- (3- (4 - ([1,1'-biphenyl] -4-yl) -6- Quinoline, the procedure of Synthesis Example 12 was carried out to obtain the desired compound (3.4 g); HRMS [M] < + >: 677.81

[[ 합성예Synthetic example 114] Mat 114의 합성 114] Synthesis of Mat 114

Figure pat00136
Figure pat00136

반응물로 8-(3-(4-([1,1'-바이페닐]-4-일)-6-페닐-1,3,5-트리아진-2-일)-5-브로모페닐)퀴놀린을 사용한 것을 제외하고는 [합성예 53]동일한 과정을 수행하여 목적 화합물 2.9g을 얻었다; HRMS [M]+: 665.80As a reaction product, 8- (3- (4 - ([1,1'-biphenyl] -4-yl) -6- Quinoline [Synthetic Example 53] By the same procedure as above, 2.9 g of the desired compound was obtained; HRMS [M] < + >: 665.80

[[ 합성예Synthetic example 115] Mat 115의 합성 115] Synthesis of Mat 115

Figure pat00137
Figure pat00137

반응물로 2-([1,1'-바이페닐]-4-일)-4-(5-브로모-4'-(피리딘-3-일)-[1,1'-바이페닐]-3-일)-6-페닐-1,3,5-트리아진을 사용한 것을 제외하고는 [합성예 54]과 동일한 과정을 수행하여 목적 화합물 2.8g을 얻었다; HRMS [M]+: 614.75The reaction was carried out using 2 - ([1,1'-biphenyl] -4-yl) -4- (5-bromo-4 ' -Yl) -6-phenyl-1,3,5-triazine was used in place of [ HRMS [M] < + >: 614.75

[[ 합성예Synthetic example 116] Mat 116의 합성 116] Synthesis of Mat 116

Figure pat00138
Figure pat00138

반응물로 2-([1,1'-바이페닐]-4-일)-4-(5-브로모-4'-(피리딘-3-일)-[1,1'-바이페닐]-3-일)-6-페닐-1,3,5-트리아진을 사용한 것을 제외하고는 [합성예 55]과 동일한 과정을 수행하여 목적 화합물 2.5g을 얻었다; HRMS [M]+: 664.81The reaction was carried out using 2 - ([1,1'-biphenyl] -4-yl) -4- (5-bromo-4 ' -Yl) -6-phenyl-1,3,5-triazine was used in place of 2-bromo-6-phenyl-1,3,5-triazine to obtain 2.5 g of the title compound. HRMS [M] < + >: 664.81

[[ 합성예Synthetic example 117] Mat 117의 합성 117] Synthesis of Mat 117

Figure pat00139
Figure pat00139

반응물로 2-([1,1'-바이페닐]-4-일)-4-(5-브로모-4'-(피리딘-3-일)-[1,1'-바이페닐]-3-일)-6-페닐-1,3,5-트리아진을 사용한 것을 제외하고는 [합성예 57]과 동일한 과정을 수행하여 목적 화합물 3.3g을 얻었다; HRMS [M]+: 714.87The reaction was carried out using 2 - ([1,1'-biphenyl] -4-yl) -4- (5-bromo-4 ' -Yl) -6-phenyl-1,3,5-triazine was used in place of 2-chloro-6-phenyl-1,3,5-triazine to obtain the desired compound (3.3 g); HRMS [M] < + >: 714.87

[[ 합성예Synthetic example 118] Mat 118의 합성 118] Synthesis of Mat 118

Figure pat00140
Figure pat00140

반응물로 2-([1,1'-바이페닐]-4-일)-4-(5-브로모-4'-(피리딘-3-일)-[1,1'-바이페닐]-3-일)-6-페닐-1,3,5-트리아진을 사용한 것을 제외하고는 [합성예 58]과 동일한 과정을 수행하여 목적 화합물 3.0g을 얻었다; HRMS [M]+: 714.87The reaction was carried out using 2 - ([1,1'-biphenyl] -4-yl) -4- (5-bromo-4 ' -Yl) -6-phenyl-1,3,5-triazine was used in place of 2-chloro-6-phenyl-1,3,5-triazine to obtain the desired compound (3.0 g); HRMS [M] < + >: 714.87

[[ 합성예Synthetic example 119] Mat 119의 합성 119] Synthesis of Mat 119

Figure pat00141
Figure pat00141

반응물로 2-([1,1'-바이페닐]-4-일)-4-(5-브로모-4'-(피리딘-3-일)-[1,1'-바이페닐]-3-일)-6-페닐-1,3,5-트리아진을 사용한 것을 제외하고는 [합성예 60]과 동일한 과정을 수행하여 목적 화합물 3.8g을 얻었다; HRMS [M]+: 764.93The reaction was carried out using 2 - ([1,1'-biphenyl] -4-yl) -4- (5-bromo-4 ' -Yl) -6-phenyl-1,3,5-triazine was used in place of 2-chloro-6-phenyl-1,3,5-triazine to obtain 3.8 g of the title compound. HRMS [M] < + >: 764.93

[[ 합성예Synthetic example 120] Mat 120의 합성 120] Synthesis of Mat 120

Figure pat00142
Figure pat00142

반응물로 2-([1,1'-바이페닐]-4-일)-4-(5-브로모-4'-(피리딘-3-일)-[1,1'-바이페닐]-3-일)-6-페닐-1,3,5-트리아진을 사용한 것을 제외하고는 [합성예 62]과 동일한 과정을 수행하여 목적 화합물 2.7g을 얻었다; HRMS [M]+: 730.92The reaction was carried out using 2 - ([1,1'-biphenyl] -4-yl) -4- (5-bromo-4 ' -Yl) -6-phenyl-1,3,5-triazine was used in place of 2-chloro-6-phenyl-1,3,5-triazine, 2.7 g of the title compound was obtained by carrying out the same procedure as in [Synthesis Example 62]; HRMS [M] < + >: 730.92

[[ 합성예Synthetic example 121] Mat 121의 합성 121] Synthesis of Mat 121

Figure pat00143
Figure pat00143

반응물로 2-([1,1'-바이페닐]-4-일)-4-(5-브로모-4'-(피리딘-3-일)-[1,1'-바이페닐]-3-일)-6-페닐-1,3,5-트리아진을 사용한 것을 제외하고는 [합성예 65]과 동일한 과정을 수행하여 목적 화합물 2.0g을 얻었다; HRMS [M]+: 703.85The reaction was carried out using 2 - ([1,1'-biphenyl] -4-yl) -4- (5-bromo-4 ' -Yl) -6-phenyl-1,3,5-triazine was used in place of 2-bromo-6-phenyl-1,3,5-triazine to obtain 2.0 g of the desired compound. HRMS [M] < + >: 703.85

[[ 합성예Synthetic example 122] Mat 122의 합성 122] Synthesis of Mat 122

Figure pat00144
Figure pat00144

반응물로 2-([1,1'-바이페닐]-4-일)-4-(5-브로모-4'-(피리딘-3-일)-[1,1'-바이페닐]-3-일)-6-페닐-1,3,5-트리아진을 사용한 것을 제외하고는 [합성예 69]과 동일한 과정을 수행하여 목적 화합물 3.1g을 얻었다; HRMS [M]+: 716.85The reaction was carried out using 2 - ([1,1'-biphenyl] -4-yl) -4- (5-bromo-4 ' -Yl) -6-phenyl-1,3,5-triazine was used in place of 2-chloro-6-phenyl-1,3,5-triazine. HRMS [M] < + >: 716.85

[[ 합성예Synthetic example 123] Mat 123의 합성 123] Synthesis of Mat 123

Figure pat00145
Figure pat00145

반응물로 2-([1,1'-바이페닐]-4-일)-4-(5-브로모-4'-(피리딘-3-일)-[1,1'-바이페닐]-3-일)-6-페닐-1,3,5-트리아진을 사용한 것을 제외하고는 [합성예 70]과 동일한 과정을 수행하여 목적 화합물 3.8g을 얻었다; HRMS [M]+: 664.81The reaction was carried out using 2 - ([1,1'-biphenyl] -4-yl) -4- (5-bromo-4 ' -Yl) -6-phenyl-1,3,5-triazine was used in place of 2-chloro-6-phenyl-1,3,5-triazine to obtain 3.8 g of the title compound. HRMS [M] < + >: 664.81

[[ 합성예Synthetic example 124] Mat 124의 합성 124] Synthesis of Mat 124

Figure pat00146
Figure pat00146

반응물로 2-(3-(4-([1,1'-바이페닐]-4-일)-6-페닐-1,3,5-트리아진-2-일)-5-브로모페닐)-1,10-페난트롤린을 사용한 것을 제외하고는 [합성예 71]과 동일한 과정을 수행하여 목적 화합물 3.0g을 얻었다; HRMS [M]+: 639.76The reaction was carried out using 2- (3- (4 - ([1,1'-biphenyl] -4-yl) -6- -1,10-phenanthroline, the procedure of Synthesis Example 71 was repeated to obtain 3.0 g of the target compound; HRMS [M] < + >: 639.76

[[ 합성예Synthetic example 125] Mat 125의 합성 125] Synthesis of Mat 125

Figure pat00147
Figure pat00147

반응물로 2-(3-(4-([1,1'-바이페닐]-4-일)-6-페닐-1,3,5-트리아진-2-일)-5-브로모페닐)-1,10-페난트롤린을 사용한 것을 제외하고는 [합성예 72]과 동일한 과정을 수행하여 목적 화합물 3.4g을 얻었다; HRMS [M]+: 689.82The reaction was carried out using 2- (3- (4 - ([1,1'-biphenyl] -4-yl) -6- -1,10-phenanthroline, the procedure of Synthesis Example 72 was repeated to obtain the desired compound (3.4 g); HRMS [M] < + >: 689.82

[[ 합성예Synthetic example 126] Mat 126의 합성 126] Synthesis of Mat 126

Figure pat00148
Figure pat00148

반응물로 2-(3-(4-([1,1'-바이페닐]-4-일)-6-페닐-1,3,5-트리아진-2-일)-5-브로모페닐)-1,10-페난트롤린을 사용한 것을 제외하고는 [합성예 74]과 동일한 과정을 수행하여 목적 화합물 4.1g을 얻었다; HRMS [M]+: 739.88The reaction was carried out using 2- (3- (4 - ([1,1'-biphenyl] -4-yl) -6- -1,10-phenanthroline was used in place of 4-fluorobenzyl bromide to obtain 4.1 g of the target compound; HRMS [M] < + >: 739.88

[[ 합성예Synthetic example 127] Mat 127의 합성 127] Synthesis of Mat 127

Figure pat00149
Figure pat00149

반응물로 2-(3-(4-([1,1'-바이페닐]-4-일)-6-페닐-1,3,5-트리아진-2-일)-5-브로모페닐)-1,10-페난트롤린을 사용한 것을 제외하고는 [합성예 77]과 동일한 과정을 수행하여 목적 화합물 4.6g을 얻었다; HRMS [M]+: 789.94The reaction was carried out using 2- (3- (4 - ([1,1'-biphenyl] -4-yl) -6- -1,10-phenanthroline, the procedure of Synthesis Example 77 was followed to obtain the desired compound (4.6 g); HRMS [M] < + >: 789.94

[[ 합성예Synthetic example 128] Mat 128의 합성 128] Synthesis of Mat 128

Figure pat00150
Figure pat00150

반응물로 2-(3-(4-([1,1'-바이페닐]-4-일)-6-페닐-1,3,5-트리아진-2-일)-5-브로모페닐)-1,10-페난트롤린을 사용한 것을 제외하고는 [합성예 79]과 동일한 과정을 수행하여 목적 화합물 3.8g을 얻었다; HRMS [M]+: 755.93The reaction was carried out using 2- (3- (4 - ([1,1'-biphenyl] -4-yl) -6- -1,10-phenanthroline, the procedure of Synthesis Example 79 was repeated to give the object compound (3.8 g); HRMS [M] < + >: 755.93

[[ 합성예Synthetic example 129] Mat 129의 합성 129] Synthesis of Mat 129

Figure pat00151
Figure pat00151

반응물로 2-(3-(4-([1,1'-바이페닐]-4-일)-6-페닐-1,3,5-트리아진-2-일)-5-브로모페닐)-1,10-페난트롤린을 사용한 것을 제외하고는 [합성예 82]과 동일한 과정을 수행하여 목적 화합물 2.6g을 얻었다; HRMS [M]+: 728.86The reaction was carried out using 2- (3- (4 - ([1,1'-biphenyl] -4-yl) -6- -1,10-phenanthroline, the procedure of Synthesis Example 82 was repeated to obtain 2.6 g of the target compound; HRMS [M] < + >: 728.86

[[ 합성예Synthetic example 130] Mat 130의 합성 130] Synthesis of Mat 130

Figure pat00152
Figure pat00152

반응물로 2-(3-(4-([1,1'-바이페닐]-4-일)-6-페닐-1,3,5-트리아진-2-일)-5-브로모페닐)-1,10-페난트롤린을 사용한 것을 제외하고는 [합성예 85]과 동일한 과정을 수행하여 목적 화합물 2.0g을 얻었다; HRMS [M]+: 744.86The reaction was carried out using 2- (3- (4 - ([1,1'-biphenyl] -4-yl) -6- -1,10-phenanthroline was used in place of 2-chloro-2-fluoroaniline to obtain 2.0 g of the target compound; HRMS [M] < + >: 744.86

[[ 합성예Synthetic example 131] Mat 131의 합성 131] Synthesis of Mat 131

Figure pat00153
Figure pat00153

반응물로 2-(3-(4-([1,1'-바이페닐]-4-일)-6-페닐-1,3,5-트리아진-2-일)-5-브로모페닐)-1,10-페난트롤린을 사용한 것을 제외하고는 [합성예 87]과 동일한 과정을 수행하여 목적 화합물 4.0g을 얻었다; HRMS [M]+: 716.85The reaction was carried out using 2- (3- (4 - ([1,1'-biphenyl] -4-yl) -6- -1,10-phenanthroline was used in place of 4-fluorobenzyl chloride, the procedure of Synthesis Example 87 was repeated to obtain 4.0 g of the target compound; HRMS [M] < + >: 716.85

[[ 실시예Example 1] 청색 유기  1] Blue organic 전계Field 발광 소자의 제조 Manufacturing of light emitting device

합성예에서 합성된 화합물을 통상적으로 알려진 방법으로 고순도 승화정제를 한 후, 하기와 같이 청색 유기 전계 발광 소자를 제조하였다.The compound synthesized in Synthesis Example was subjected to high purity sublimation purification by a conventionally known method, and then a blue organic electroluminescent device was produced as follows.

ITO (Indium tin oxide)가 1500 Å 두께로 박막 코팅된 유리 기판을 증류수 초음파로 세척하였다. 증류수 세척이 끝나면, 이소프로필 알코올, 아세톤, 메탄올 등의 용제로 초음파 세척을 하고, 건조시킨 후, UV OZONE 세정기(Power sonic 405, 화신테크)로 이송시킨 다음, UV를 이용하여 상기 기판을 5분간 세정하고 진공 증착기로 기판을 이송하였다.Glass substrate coated with ITO (Indium tin oxide) thin film with thickness of 1500 Å was washed with distilled water ultrasonic wave. After the distilled water was washed, it was ultrasonically washed with a solvent such as isopropyl alcohol, acetone, or methanol, dried, transferred to a UV OZONE cleaner (Power sonic 405, Hoshin Tech) And the substrate was transferred to a vacuum evaporator.

상기와 같이 준비된 ITO 투명 전극 위에, DS-205 (80 nm)/NPB (15 nm)/ADN + 5 % DS-405 (30nm)/합성예 1의 합성예의 화합물(30 nm)/LiF (1 nm)/Al (200 nm) 순으로 적층하여 유기 전계 발광 소자를 제조하였다.(30 nm) / LiF (1 nm) of Synthesis Example 1 of Synthesis Example 1 was added to the ITO transparent electrode prepared as described above, DS-205 (80 nm) / NPB (15 nm) / ADN + 5% DS- ) / Al (200 nm) were stacked in this order to produce an organic electroluminescent device.

이때 사용된 NPB, ADN 및 Alq3의 구조는 다음과 같다.The structures of NPB, ADN and Alq 3 used in this case are as follows.

Figure pat00154
Figure pat00154

[[ 비교예Comparative Example 1] 청색1] blue 유기  abandonment 전계Field 발광 소자의 제조 Manufacturing of light emitting device

수명 개선층을 포함하지 않고, 전자 수송층 물질인 Alq3을 30nm로 증착하는 것을 제외하고는, 실시예 1과 동일하게 수행하여 청색 유기 전계 발광 소자를 제작하였다. A blue organic electroluminescent device was fabricated in the same manner as in Example 1, except that the lifetime improving layer was not included and the electron transport layer material Alq 3 was deposited at 30 nm.

[[ 평가예Evaluation example 1] One]

실시예 1 내지 62 및 비교예 1에서 각각 제조된 유기 전계 발광 소자에 대하여, 전류밀도 10 mA/㎠에서의 구동전압, 전류효율, 발광파장을 측정하였고, 그 결과를 하기 표 1에 나타내었다.The driving voltage, current efficiency and emission wavelength at the current density of 10 mA / cm 2 were measured for the organic electroluminescent devices manufactured in Examples 1 to 62 and Comparative Example 1, respectively, and the results are shown in Table 1 below.

샘플Sample 전자수송층Electron transport layer 구동전압
(V)
Driving voltage
(V)
전류효율
(cd/A)
Current efficiency
(cd / A)
발광피크
(nm)
Emission peak
(nm)
실시예1Example 1 1One 4.04.0 5.95.9 458458 실시예2Example 2 22 4.24.2 5.85.8 458458 실시예3Example 3 33 4.34.3 5.95.9 459459 실시예4Example 4 44 4.14.1 5.85.8 458458 실시예5Example 5 55 4.54.5 5.95.9 458458 실시예6Example 6 66 4.04.0 6.06.0 458458 실시예7Example 7 77 4.14.1 6.06.0 458458 실시예8Example 8 88 4.14.1 6.16.1 459459 실시예9Example 9 99 4.24.2 5.85.8 457457 실시예10Example 10 1010 4.64.6 5.85.8 458458 실시예11Example 11 1111 4.54.5 5.95.9 458458 실시예12Example 12 1212 4.44.4 5.95.9 458458 실시예13Example 13 1313 4.14.1 5.75.7 458458 실시예14Example 14 1414 4.14.1 5.95.9 459459 실시예15Example 15 1515 4.04.0 5.95.9 458458 실시예16Example 16 1616 4.24.2 6.06.0 458458 실시예17Example 17 1717 4.34.3 6.06.0 458458 실시예18Example 18 1818 4.14.1 6.16.1 458458 실시예19Example 19 1919 4.54.5 5.85.8 459459 실시예20Example 20 2020 4.04.0 5.85.8 458458 실시예21Example 21 2121 4.24.2 5.95.9 458458 실시예22Example 22 2222 4.34.3 5.95.9 459459 실시예23Example 23 2323 4.14.1 5.95.9 458458 실시예24Example 24 2424 4.54.5 5.85.8 458458 실시예25Example 25 2525 4.04.0 5.95.9 458458 실시예26Example 26 2626 4.34.3 6.06.0 458458 실시예27Example 27 2727 4.54.5 6.06.0 459459 실시예28Example 28 2828 4.44.4 6.16.1 457457 실시예29Example 29 2929 4.14.1 5.85.8 458458 실시예30Example 30 3030 4.14.1 5.85.8 458458 실시예31Example 31 3131 4.04.0 5.95.9 458458 실시예32Example 32 3232 4.14.1 5.95.9 458458 실시예33Example 33 3333 4.34.3 5.75.7 458458 실시예34Example 34 5252 4.34.3 5.95.9 458458 실시예35Example 35 5454 4.24.2 5.85.8 458458 실시예36Example 36 5555 4.04.0 5.95.9 459459 실시예37Example 37 5656 4.24.2 6.06.0 458458 실시예38Example 38 5959 4.34.3 5.95.9 458458 실시예39Example 39 6060 4.14.1 6.06.0 458458 실시예40Example 40 6161 4.54.5 6.06.0 458458 실시예41Example 41 6363 4.04.0 6.16.1 458458 실시예42Example 42 6464 4.04.0 5.85.8 459459 실시예43Example 43 6565 4.24.2 5.85.8 458458 실시예44Example 44 6666 4.34.3 5.95.9 458458 실시예45Example 45 6767 4.14.1 5.95.9 458458 실시예46Example 46 7070 4.54.5 5.75.7 458458 실시예47Example 47 7171 4.04.0 5.95.9 459459 실시예48Example 48 7272 4.14.1 5.85.8 457457 실시예49Example 49 7373 4.14.1 5.95.9 458458 실시예50Example 50 7575 4.24.2 6.06.0 458458 실시예51Example 51 7676 4.14.1 6.16.1 458458 실시예52Example 52 7777 4.14.1 5.85.8 459459 실시예53Example 53 7878 4.04.0 5.85.8 457457 실시예54Example 54 7979 4.14.1 5.95.9 458458 실시예55Example 55 8080 4.24.2 5.95.9 458458 실시예56Example 56 8282 4.44.4 5.75.7 458458 실시예57Example 57 8383 4.44.4 5.95.9 458458 실시예58Example 58 8484 4.54.5 5.85.8 459459 실시예59Example 59 8888 4.24.2 5.95.9 458458 실시예60Example 60 9090 4.14.1 5.95.9 458458 실시예61Example 61 100100 4.54.5 5.95.9 457457 실시예62Example 62 101101 4.24.2 5.75.7 458458 비교예 1Comparative Example 1 Alq3 Alq 3 4.7 4.7 5.6 5.6 458 458

상기 표 1을 살펴보면, 본 발명의 화학식 1로 표시되는 화합물을 전자수송층에 사용하는 실시예 1~62의 유기 EL 소자는 종래 Alq3를 전자수송층에 사용하는 비교예 1의 유기 EL 소자보다 전류효율 및 구동전압 면에서 우수한 성능을 나타내는 것을 확인할 수 있었다.As shown in Table 1, the organic EL devices of Examples 1 to 62 using the compound represented by Formula 1 of the present invention as the electron transport layer exhibited higher current efficiency than the organic EL device of Comparative Example 1 using Alq 3 as the electron transport layer And the driving voltage.

Claims (10)

하기 화학식 1로 표시되는 화합물:
[화학식 1]
Figure pat00155

여기서,
L1 및 L2는 서로 동일하거나 상이하며, 단일결합, C6~C18의 아릴렌기 또는 핵원자수 5 내지 18의 헤테로아릴렌기이며,
R1 및 R2는 서로 동일하거나 상이하며, 각각 독립적으로 C6~C60의 아릴기 또는 핵원자수 5 내지 60의 헤테로아릴기이며;
Ar1 및 Ar2는 서로 상이하며, 각각 독립적으로 C6~C60의 아릴기 또는 핵원자수 5 내지 60의 헤테로아릴기이며,
X1, X2 및 X3는 서로 동일하거나 상이하며, 각각 독립적으로 N 또는 C(R3)이며, 적어도 2개 이상은 N이며;
R3는 서로 동일하거나 상이하며, 각각 독립적으로 수소, 중수소, 할로겐, 시아노기, 니트로기, C1~C40의 알킬기, C2~C40의 알케닐기, C2~C40의 알키닐기, C3~C40의 시클로알킬기, 핵원자수 3 내지 40의 헤테로시클로알킬기, C6~C60의 아릴기, 핵원자수 5 내지 60의 헤테로아릴기, C1~C40의 알킬옥시기, C6~C60의 아릴옥시기, C3~C40의 알킬실릴기, C6~C60의 아릴실릴기, C1~C40의 알킬보론기, C6~C60의 아릴보론기, C6~C60의 아릴포스핀기, C6~C60의 아릴포스핀옥사이드기 및 C6~C60의 아릴아민기로 이루어진 군으로부터 선택되고,
L1 L2의 아릴렌기 및 헤테로아릴렌기와 R1 내지 R3 및 Ar1 내지 Ar2의 아릴기 및 헤테로아릴기는 각각 독립적으로, 중주소, 시아노기, 할로겐, C1~C40의 알킬기, C2~C40의 알케닐기, C2~C40의 알키닐기, C3~C40의 시클로알킬기, 핵원자수 3 내지 40의 헤테로시클로알킬기, C6~C60의 아릴기, 핵원자수 5 내지 60의 헤테로아릴기, C1~C40의 알킬옥시기, C6~C60의 아릴옥시기,C3~C40의 알킬실릴기, C6~C60의 아릴실릴기, C1~C40의 알킬보론기, C6~C60의 아릴보론기, C6~C60의 아릴포스핀기, C6~C60의 아릴포스핀옥사이드기 및 C6~C60의 아릴아민기로 이루어진 군에서 선택된 1종 이상으로 치환될 수 있으며, 복수개의 치환기로 치환될 경우 이들은 서로 동일하거나 상이할 수 있다.
A compound represented by the following formula (1):
[Chemical Formula 1]
Figure pat00155

here,
L 1 and L 2 are the same or different and each is a single bond, a C 6 to C 18 arylene group or a heteroarylene group having 5 to 18 nuclear atoms,
R 1 and R 2 are the same or different and are each independently a C 6 to C 60 aryl group or a heteroaryl group having 5 to 60 nuclear atoms;
Ar 1 and Ar 2 are different from each other and are each independently a C 6 to C 60 aryl group or a heteroaryl group having 5 to 60 nuclear atoms,
X 1 , X 2 and X 3 are the same or different and are each independently N or C (R 3 ), and at least two are N;
R 3 are the same or different and are each independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, nitro, C 1 to C 40 alkyl, C 2 to C 40 alkenyl, C 2 to C 40 alkynyl, A C 3 to C 40 cycloalkyl group, a heterocycloalkyl group having 3 to 40 nuclear atoms, a C 6 to C 60 aryl group, a heteroaryl group having 5 to 60 nuclear atoms, a C 1 to C 40 alkyloxy group, A C 6 to C 60 aryloxy group, a C 3 to C 40 alkylsilyl group, a C 6 to C 60 arylsilyl group, a C 1 to C 40 alkylboron group, a C 6 to C 60 arylboron group, C 6 ~ C 60 aryl phosphine group, C 6 ~ C 60 aryl phosphine oxide group, and a C 6 ~ C 60 aryl group of an amine of is selected from the group consisting of,
L 1 and The arylene group and the heteroarylene group of L 2 and the aryl group and heteroaryl group of R 1 to R 3 and Ar 1 to Ar 2 are each independently a lower alkyl group, a cyano group, a halogen, a C 1 to C 40 alkyl group, a C 2 ~ C 40 alkenyl group, C 2 ~ C 40 alkynyl group, C 3 ~ C 40 cycloalkyl group, a number of nuclear atoms of 3 to 40 heterocycloalkyl group, C 6 ~ C 60 aryl group, the number of nuclear atoms of 5 to the a heteroaryl group of 60, C 1 ~ C 40 alkyloxy group of, C 6 ~ C 60 aryloxy group, C 3 ~ C 40 alkylsilyl group, a C 6 ~ C 60 aryl silyl group, C 1 ~ C of 40 groups of an alkyl boron, C 6 ~ C 60 aryl boron group, C 6 ~ C 60 aryl phosphine group, C 6 ~ C 60 aryl phosphine oxide group, and a C 6 ~ from the group consisting of an aryl amine of the C 60 And when they are substituted with a plurality of substituents, they may be the same or different from each other.
제 1항에 있어서,
상기 Ar1 및 Ar2는 서로 상이하며, 각각 독립적으로 C6~C60의 아릴기인 화합물.
The method according to claim 1,
Wherein Ar 1 and Ar 2 are different from each other, and each independently is a C 6 to C 60 aryl group.
제 1항에 있어서,
상기 X1 및 X2는 각각 독립적으로 N이고,
상기 X3는 N 또는 C(R3)에서 선택되고,
상기 Ar1 및 Ar2는 서로 상이하며, 각각 독립적으로 페닐 또는 바이페닐에서 선택되는 화합물.
The method according to claim 1,
X 1 and X 2 are each independently N,
It said X 3 is selected from N or C (R 3),
Wherein Ar 1 and Ar 2 are different from each other and are each independently selected from phenyl or biphenyl.
제 1항에 있어서,
상기 R1 및 R2는 서로 동일하거나 상이하며, 각각 독립적으로 C6~C60의 아릴기 또는 핵원자수 5 내지 60의 헤테로아릴기에서 선택되는 화합물.
The method according to claim 1,
Wherein R 1 and R 2 are the same or different and are each independently selected from a C 6 to C 60 aryl group or a heteroaryl group having 5 to 60 nuclear atoms.
제 1항에 있어서,
상기 R1 또는 R2 중 적어도 하나는 하기 화학식 2 내지 5의 치환기로 이루어진 군으로부터 선택되는 것인 화합물:
[화학식 2]
Figure pat00156

[화학식 3]
Figure pat00157

[화학식 4]
Figure pat00158

[화학식 5]
Figure pat00159

여기서,
*는 상기 화학식 1에 결합되는 부분을 의미하고;
X4 내지 X26은 서로 동일하고 상이하며, 각각 독립적으로 N 또는 C(R5)이며,
R5는 서로 동일하거나 상이하며, 각각 독립적으로 수소, 중수소, 할로겐, 시아노기, 니트로기, C1~C40의 알킬기, C2~C40의 알케닐기, C2~C40의 알키닐기, C3~C40의 시클로알킬기, 핵원자수 3 내지 40의 헤테로시클로알킬기, C6~C60의 아릴기, 핵원자수 5 내지 60의 헤테로아릴기, C1~C40의 알킬옥시기, C6~C60의 아릴옥시기, C3~C40의 알킬실릴기, C6~C60의 아릴실릴기, C1~C40의 알킬보론기, C6~C60의 아릴보론기, C6~C60의 아릴포스핀기, C6~C60의 아릴포스핀옥사이드기 및 C6~C60의 아릴아민기로 이루어진 군으로부터 선택되고,
R5의 알킬기, 시클로알킬기, 헤테로시클로알킬기, 아릴기, 헤테로아릴기, 알킬옥시기, 아릴옥시기, 알킬실릴기, 아릴실릴기, 알킬보론기, 아릴보론기, 아릴포스핀기, 아릴포스핀옥사이드기 및 아릴아민기는 각각 독립적으로, C1~C40의 알킬기, C2~C40의 알케닐기, C2~C40의 알키닐기, C3~C40의 시클로알킬기, 핵원자수 3 내지 40의 헤테로시클로알킬기, C6~C60의 아릴기, 핵원자수 5 내지 60의 헤테로아릴기, C1~C40의 알킬옥시기, C6~C60의 아릴옥시기,C3~C40의 알킬실릴기, C6~C60의 아릴실릴기, C1~C40의 알킬보론기, C6~C60의 아릴보론기, C6~C60의 아릴포스핀기, C6~C60의 아릴포스핀옥사이드기 및 C6~C60의 아릴아민기로 이루어진 군으로부터 선택된 1종 이상으로 치환될 수 있으며, 복수개의 치환기로 치환될 경우 이들은 서로 동일하거나 상이할 수 있다.
The method according to claim 1,
The compound will be at least one of the R 1 or R 2 is selected from the group consisting of substituents of Formulas 2 to 5:
(2)
Figure pat00156

(3)
Figure pat00157

[Chemical Formula 4]
Figure pat00158

[Chemical Formula 5]
Figure pat00159

here,
* Represents a moiety bonded to Formula 1;
X 4 to X 26 are the same or different and are each independently N or C (R 5 )
R 5 are the same or different and are each independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, nitro, C 1 to C 40 alkyl, C 2 to C 40 alkenyl, C 2 to C 40 alkynyl, A C 3 to C 40 cycloalkyl group, a heterocycloalkyl group having 3 to 40 nuclear atoms, a C 6 to C 60 aryl group, a heteroaryl group having 5 to 60 nuclear atoms, a C 1 to C 40 alkyloxy group, A C 6 to C 60 aryloxy group, a C 3 to C 40 alkylsilyl group, a C 6 to C 60 arylsilyl group, a C 1 to C 40 alkylboron group, a C 6 to C 60 arylboron group, C 6 ~ C 60 aryl phosphine group, C 6 ~ C 60 aryl phosphine oxide group, and a C 6 ~ C 60 aryl group of an amine of is selected from the group consisting of,
R 5 is an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, an alkyloxy group, an aryloxy group, an alkylsilyl group, an arylsilyl group, an alkylboron group, an arylboron group, an arylphosphine group, The oxides and arylamine groups are each independently selected from the group consisting of a C 1 to C 40 alkyl group, a C 2 to C 40 alkenyl group, a C 2 to C 40 alkynyl group, a C 3 to C 40 cycloalkyl group, A C 6 to C 60 aryl group, a heteroaryl group having 5 to 60 nuclear atoms, a C 1 to C 40 alkyloxy group, a C 6 to C 60 aryloxy group, a C 3 to C 6 heteroaryl group, 40 alkylsilyl group, C 6 ~ C 60 aryl silyl group, C 1 ~ C 40 group of an alkyl boron, C 6 ~ C group 60 arylboronic of, C 6 ~ aryl phosphine of C 60 pingi, C 6 ~ C aryl phosphine oxide group and a C 6 ~ 60 may be substituted with at least one member selected from the group consisting of an aryl amine of the C 60, the case be substituted with a plurality of substituents, they same or another It may be different.
제 1항에 있어서,
상기 화합물은 아래의 화합물로 이루어진 군에서 선택되는 것을 특징으로 하는 화합물:
Figure pat00160

Figure pat00161

Figure pat00162

Figure pat00163
The method according to claim 1,
Wherein said compound is selected from the group consisting of:
Figure pat00160

Figure pat00161

Figure pat00162

Figure pat00163
(i) 양극, (ii) 음극, 및 (iii) 상기 양극과 음극 사이에 개재(介在)된 1층 이상의 유기물층을 포함하는 유기 전계 발광 소자로서,
상기 1층 이상의 유기물층 중에서 적어도 하나는 제1항에 따른 화학식 1로 표시되는 화합물을 포함하는 것인 유기 전계 발광 소자.
1. An organic electroluminescent device comprising: (i) an anode, (ii) a cathode, and (iii) one or more organic layers sandwiched between the anode and the cathode,
Wherein at least one of the one or more organic layers includes a compound represented by Formula 1 according to Claim 1.
제7항에 있어서,
상기 유기물층은 발광층, 발광 보조층, 정공 수송층, 정공 주입층, 전자 수송층 및 전자 주입층으로 이루어진 군으로부터 선택되는 유기 전계 발광 소자.
8. The method of claim 7,
Wherein the organic material layer is selected from the group consisting of a light emitting layer, a light emitting auxiliary layer, a hole transporting layer, a hole injecting layer, an electron transporting layer, and an electron injecting layer.
제7항에 있어서,
상기 유기물층은 발광층, 정공 수송층 및 전자 수송층으로 이루어진 군으로부터 선택되는 유기 전계 발광 소자.
8. The method of claim 7,
Wherein the organic material layer is selected from the group consisting of a light emitting layer, a hole transporting layer, and an electron transporting layer.
제7항에 있어서,
상기 유기물층은 전자수송층인 것을 특징으로 하는 유기 전계 발광 소자.
8. The method of claim 7,
Wherein the organic material layer is an electron transporting layer.
KR1020160044337A 2016-04-11 2016-04-11 Organic light-emitting compound and organic electroluminescent device using the same KR20170116500A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR1020160044337A KR20170116500A (en) 2016-04-11 2016-04-11 Organic light-emitting compound and organic electroluminescent device using the same
PCT/KR2017/001668 WO2017179809A1 (en) 2016-04-11 2017-02-15 Organic light-emitting compound and organic electroluminescent element using same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020160044337A KR20170116500A (en) 2016-04-11 2016-04-11 Organic light-emitting compound and organic electroluminescent device using the same

Publications (1)

Publication Number Publication Date
KR20170116500A true KR20170116500A (en) 2017-10-19

Family

ID=60042639

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020160044337A KR20170116500A (en) 2016-04-11 2016-04-11 Organic light-emitting compound and organic electroluminescent device using the same

Country Status (2)

Country Link
KR (1) KR20170116500A (en)
WO (1) WO2017179809A1 (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180022574A (en) * 2016-08-23 2018-03-06 주식회사 두산 Organic compounds and organic electro luminescence device comprising the same
WO2019093547A1 (en) * 2017-11-10 2019-05-16 주식회사 진웅산업 Phenanthroline-anthracene compound and organic light emitting device comprising same
WO2019093545A1 (en) * 2017-11-09 2019-05-16 주식회사 진웅산업 Phenanthroline compound and organic light emitting device comprising same
JP2020033264A (en) * 2018-08-27 2020-03-05 東ソー株式会社 Triazine compound having naphthylene group
WO2020130726A1 (en) * 2018-12-21 2020-06-25 두산솔루스 주식회사 Organic compound and organic electroluminescent diode comprising same
KR20200075555A (en) 2018-12-18 2020-06-26 두산솔루스 주식회사 Organic light-emitting compound and organic electroluminescent device using the same
WO2020218648A1 (en) * 2019-04-25 2020-10-29 주식회사 진웅산업 Phenanthroline compound and organic light-emitting device comprising same
CN112239452A (en) * 2020-10-14 2021-01-19 武汉尚赛光电科技有限公司 Electron transport type heteroanthracene derivative and organic electroluminescent device thereof
CN112358473A (en) * 2020-10-14 2021-02-12 武汉尚赛光电科技有限公司 Heteroanthracene derivative, application thereof and organic electroluminescent device
CN113651809A (en) * 2020-05-12 2021-11-16 三星显示有限公司 Organic electroluminescent device and compound for organic electroluminescent device
WO2023085637A1 (en) * 2021-11-11 2023-05-19 주식회사 엘지화학 Compound and organic light-emitting device comprising same
US11690289B2 (en) 2019-12-03 2023-06-27 Samsung Display Co., Ltd. Organic compound containing heterocyclic ring and having low lumo properties, and organic electroluminescent device using the same
US11937501B2 (en) 2020-04-13 2024-03-19 Samsung Display Co., Ltd. Heterocyclic compound and organic light- emitting device including heterocyclic compound

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI630260B (en) * 2017-12-21 2018-07-21 昱鐳光電科技股份有限公司 Quinoline-substituted diphenylpyrimidines compounds and organic electroluminescent devices using the same
CN109251194A (en) * 2018-09-11 2019-01-22 长春海谱润斯科技有限公司 A kind of triaizine compounds and its organic luminescent device of the class formation containing fluorenes
WO2021020285A1 (en) * 2019-07-30 2021-02-04 東ソー株式会社 Cyclic azine compound, material for organic electroluminescent element, electron transport material for organic electroluminescent element, and organic electroluminescent element
CN110981860A (en) * 2019-12-27 2020-04-10 陕西莱特光电材料股份有限公司 Heterocyclic compound, method for synthesizing same, organic electroluminescent device, and electronic apparatus
CN112159348B (en) 2020-08-07 2022-03-11 陕西莱特光电材料股份有限公司 Nitrogen-containing compound, electronic component, and electronic device
CN112321585B (en) * 2020-10-30 2022-04-22 华南理工大学 Asymmetric substituted diphenyl pyridine compound and preparation and application thereof
CN117279912A (en) 2021-01-29 2023-12-22 出光兴产株式会社 Compound, material for organic electroluminescent element, and electronic device
JP2022179374A (en) * 2021-05-19 2022-12-02 東ソー株式会社 Pyrimidine compound, material for organic electroluminescent elements, and organic electroluminescent element

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013175746A1 (en) * 2012-05-22 2013-11-28 出光興産株式会社 Organic electroluminescent element
JP2016122672A (en) * 2013-03-18 2016-07-07 出光興産株式会社 Light emitting device
US9755159B2 (en) * 2014-01-23 2017-09-05 Universal Display Corporation Organic materials for OLEDs
KR101770463B1 (en) * 2014-05-15 2017-08-23 주식회사 엘지화학 Hetero-cyclic compound and organic light emitting device comprising the same
US10297762B2 (en) * 2014-07-09 2019-05-21 Universal Display Corporation Organic electroluminescent materials and devices
US10749113B2 (en) * 2014-09-29 2020-08-18 Universal Display Corporation Organic electroluminescent materials and devices

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180022574A (en) * 2016-08-23 2018-03-06 주식회사 두산 Organic compounds and organic electro luminescence device comprising the same
WO2019093545A1 (en) * 2017-11-09 2019-05-16 주식회사 진웅산업 Phenanthroline compound and organic light emitting device comprising same
KR20190052882A (en) * 2017-11-09 2019-05-17 주식회사 진웅산업 phenanthroline compound and organic light emitting element comprising the same
WO2019093547A1 (en) * 2017-11-10 2019-05-16 주식회사 진웅산업 Phenanthroline-anthracene compound and organic light emitting device comprising same
JP2020033264A (en) * 2018-08-27 2020-03-05 東ソー株式会社 Triazine compound having naphthylene group
KR20200075555A (en) 2018-12-18 2020-06-26 두산솔루스 주식회사 Organic light-emitting compound and organic electroluminescent device using the same
WO2020130726A1 (en) * 2018-12-21 2020-06-25 두산솔루스 주식회사 Organic compound and organic electroluminescent diode comprising same
KR20200077951A (en) 2018-12-21 2020-07-01 두산솔루스 주식회사 Organic compounds and organic electro luminescence device comprising the same
WO2020218648A1 (en) * 2019-04-25 2020-10-29 주식회사 진웅산업 Phenanthroline compound and organic light-emitting device comprising same
KR20200124970A (en) * 2019-04-25 2020-11-04 주식회사 진웅산업 Phenanthroline compound and organic light emitting element comprising the same
CN113811531A (en) * 2019-04-25 2021-12-17 株式会社进雄产业 Phenanthroline compound and organic light emitting device including same
US11690289B2 (en) 2019-12-03 2023-06-27 Samsung Display Co., Ltd. Organic compound containing heterocyclic ring and having low lumo properties, and organic electroluminescent device using the same
US11937501B2 (en) 2020-04-13 2024-03-19 Samsung Display Co., Ltd. Heterocyclic compound and organic light- emitting device including heterocyclic compound
CN113651809A (en) * 2020-05-12 2021-11-16 三星显示有限公司 Organic electroluminescent device and compound for organic electroluminescent device
CN112239452A (en) * 2020-10-14 2021-01-19 武汉尚赛光电科技有限公司 Electron transport type heteroanthracene derivative and organic electroluminescent device thereof
CN112358473A (en) * 2020-10-14 2021-02-12 武汉尚赛光电科技有限公司 Heteroanthracene derivative, application thereof and organic electroluminescent device
CN112239452B (en) * 2020-10-14 2022-05-10 武汉尚赛光电科技有限公司 Electron transport type heteroanthracene derivative and organic electroluminescent device thereof
WO2023085637A1 (en) * 2021-11-11 2023-05-19 주식회사 엘지화학 Compound and organic light-emitting device comprising same

Also Published As

Publication number Publication date
WO2017179809A1 (en) 2017-10-19

Similar Documents

Publication Publication Date Title
KR102611736B1 (en) Organic light-emitting compound and organic electroluminescent device using the same
KR101742436B1 (en) Organic compounds and organic electro luminescence device comprising the same
KR20170116500A (en) Organic light-emitting compound and organic electroluminescent device using the same
KR102633650B1 (en) Organic compounds and organic electro luminescence device comprising the same
KR20180022574A (en) Organic compounds and organic electro luminescence device comprising the same
KR20190004517A (en) Organic compound and organic electroluminescent device using the same
KR20200120560A (en) Organic compounds and organic electro luminescence device comprising the same
KR20190055538A (en) Organic compound and organic electroluminescent device using the same
KR101506793B1 (en) Organic electro luminescence device
KR102160326B1 (en) Organic compounds and organic electro luminescence device comprising the same
KR101571592B1 (en) Organic compound and organic electroluminescent device comprising the same
KR20200077949A (en) Organic light-emitting compound and organic electroluminescent device using the same
KR20190058748A (en) Organic light-emitting compound and organic electroluminescent device using the same
KR102599592B1 (en) Organic compound and organic electroluminescent device using the same
KR20160076881A (en) Organic light-emitting compound and organic electroluminescent device comprising the same
KR20200075555A (en) Organic light-emitting compound and organic electroluminescent device using the same
KR102390972B1 (en) Organic compounds and organic electro luminescence device comprising the same
KR20200120561A (en) Organic compounds and organic electro luminescence device comprising the same
KR102248651B1 (en) Organic compound and organic electroluminescent device using the same
KR102358032B1 (en) Organic compounds and organic electro luminescence device comprising the same
KR20170065283A (en) Organic light-emitting compound and organic electroluminescent device using the same
KR20210062314A (en) Organic compound and organic electroluminescent device using the same
KR102508487B1 (en) Organic compounds and organic electro luminescence device comprising the same
KR20200119648A (en) Organic compound and organic electroluminescent device using the same
KR20150086107A (en) Organic compounds and organic electro luminescence device comprising the same

Legal Events

Date Code Title Description
E902 Notification of reason for refusal
E902 Notification of reason for refusal